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ABSTRACT 
 
Jeanette Baran-Gale: Dynamics of mRNA and microRNA expression in the estrogen response 
of breast cancer cells 
(Under the direction of Praveen Sethupathy and Jeremy Purvis) 
 
Cellular signaling leads to broad changes in gene expression that reprogram the cell and 
alter cell state. Signaling often begins with cellular receptors binding a ligand and initiating a 
transcriptional response. One example of this is the estrogen receptor, which binds the ligand 
estrogen and translocates to the nucleus where it binds to estrogen response elements and 
regulates the expression numerous target RNAs. The regulatory network of both messenger 
RNAs (mRNAs) and microRNAs (miRNAs) responding to estrogen stimulation is a complex, 
dynamic and multilayered program that is critical to the etiology of breast cancer. 
Estrogen receptor α (ERα) is an important biomarker of breast cancer severity and a 
common therapeutic target. Recent studies have demonstrated that in addition to its role in 
promoting proliferation, ERα also protects tumors against metastatic transformation. Current 
therapeutic strategies inhibit estrogen stimulated signaling and interfere with both beneficial and 
detrimental signaling pathways regulated by ERα. Additionally, ERα cyclically binds estrogen 
response elements and induces bursts of transcriptional activity. Together these observations 
suggest that ERα regulated genes and miRNAs may exhibit temporal variation in expression. 
Furthermore, it remains unclear if estrogen stimulated pathways exhibit the same temporal 
expression patterns, or if different pathways exhibit different temporal expression patterns. 
By combining both RNA-sequencing and small RNA-sequencing of cells responding to 
estrogen, we uncover the dynamics of both mRNA and miRNA expression in response to 
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estrogen stimulation. Furthermore, we identify a regulatory circuit with potential therapeutic 
relevance to breast cancer that more specifically inhibits ERα-stimulated growth and survival 
pathways without interfering with its protective features. In response to estrogen stimulation, 
MCF7 cells (an estrogen receptor positive model cell line) exhibit induction of miR-503, and 
repression of the oncogene ZNF217. miR-503 inhibits proliferation in MCF7 cells, in part 
through its inhibition of the oncogene ZNF217 and the cell-cycle gene CCND1. While numerous 
regulatory interactions can be mined from this temporal profile of estrogen responsive mRNAs 
and miRNAs, the induction of the anti-proliferative microRNA, miR-503, both highlights the 
protective aspects of estrogen signaling and indicates that miR-503 holds promise as a 
therapeutic for breast cancer.  
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CHAPTER 1 
 
Introduction 
Biological processes are dynamic in that they involve molecular changes over time. 
Information about a biological signal is often encoded not only in the level of protein expression, 
but also in the temporal pattern of expression of that protein. For example, the tumor suppressor 
p53 exhibits different dynamical patterns of expression in response to different stresses [1]. 
Furthermore, the temporal dynamics of p53 expression lead to activation of different cellular 
fates[2]. In another example, the MAPK pathway can be stimulated by either epidermal or 
neuronal growth factor (EGF or NGF) in a model of neuronal differentiation. These growth 
factors stimulate different dynamical patterns of behavior in Erk activation, and those differences 
in Erk dynamics encode different cellular fates (differentiation or proliferation for NGF or EGF 
respectively) [3]. These complex behaviors are possible due to the underlying regulatory 
architecture, and the most direct way to uncover that architecture is to use time-series 
experiments to measure not only levels of expression but also the dynamics of targets. 
 
1.1 Dynamic RNA expression 
Gene expression profiling of RNAs by high throughput sequencing enables us to 
measure the expression of thousands of genes in one experiment. By conducting multiple RNA-
seq experiments we can get a measure of the average temporal pattern of expression of those 
genes. This temporal pattern of expression can be used to make inferences about the 
underlying regulatory architecture. Different network architectures can result in distinct temporal 
patterns of gene expression from simple activation or repression to oscillations, pulses and even 
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multi-stability[4,5]. For example, an incoherent feed-forward loop, in which two signaling 
pathways controlled by the same upstream factor exert opposite stimuli on a downstream target, 
can lead to a transient pulse in gene expression [4]. 
Regulatory networks can be controlled at both the transcriptional and post-transcriptional 
level. One mechanism of post-transcriptional regulation is by microRNA (miRNA) mediated 
translational inhibition or mRNA degradation[6]. miRNA mediated regulatory networks frequently 
take the form of incoherent feed forward loops that can fine-tune the level of expression of a 
target protein, or coherent feed forward loops that often act to repress “leaky” transcription [5]. 
Accordingly, the combined temporal profile of both mRNA and miRNA expression can greatly 
enhance our understanding of the regulatory architecture of biological signaling networks. 
 
1.2 Post-transcriptional repression by microRNAs 
1.2.1 microRNA introduction 
miRNAs are short (~ 22 nucleotide) non-coding RNAs that act as post-transcriptional 
regulators of target RNAs (primarily mRNAs) [7]. The biogenesis of miRNAs begins with 
transcription of the primary transcripts (pri-miRNAs) by RNA pol II in the nucleus [8]. Next, the 
RNase III enzyme Drosha in conjunction with its partner DGCR8 cleaves the pri-miRNA[9]. 
These enzymes form the Microprocessor complex, which binds to the base of a stem-loop 
structure in the pri-miRNA and cleaves the transcript into a hairpin shaped miRNA precursor 
(pre-miRNA)[9]. The pre-miRNA is transported out of the nucleus with the aid of exportin 5 [9]. 
In the cytosol, pre-miRNAs undergo a second cleavage, by the RNase III enzyme Dicer[9]. This 
final cleavage produces a miRNA duplex containing a guide and passenger strand. At this point 
the duplex is loaded into the RNA Induced Silencing Complex (RISC), and either the 5’-arm or 
the 3’-arm of the duplex can be selected to guide RISC to target RNAs[9]. Selection of the 5’- or 
3’-arm is determined by the stability of the RNA duplex at the cleavage sites, where the arm 
having relatively less stability at its 5’-end is typically selected as the guide strand[9]. Finally the 
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mature miRNA is used as a guide to tether RISC to target sites that exist primarily within the 3’-
untranslated region of mRNAs, leading to repression of the target RNA [8]. Target sites are 
determined by reverse complementary binding of the “seed region” (nucleotides 2-8) of the 
miRNA to the target RNA. miRNA regulation of target mRNAs can lead to either the 
deadenylation and consequent degradation of the target mRNA or the inhibition of translation of 
the target mRNA[6]. In either case, miRNAs act as repressors of their targets. Emerging 
research has uncovered that a subset of miRNAs have an alternate function within the nucleus 
as global activators of gene expression[10]. Activation of gene expression by miRNAs remains a 
nascent field of study and is not considered further here. 
 
1.2.2 Considerations for small RNA-sequencing 
Quantification of miRNA expression by high throughput sequencing (HTS) is subject to 
several issues / challenges. miRNA species are (1) short, (2) subject to non-templated 
modifications that can occur anywhere within the miRNA sequence but are most prominent at 
the 3’-end [11], and (3) subject to significant bias in HTS [12-15]. Detailed quantification of 
sequenced miRNA species (including any variants, termed isomiRs) requires the use of a 
custom alignment pipeline; as such I developed the miRquant pipeline (discussed in Chapter 2). 
This pipeline was prototyped by quantifying the miRNAs and isomiRs expressed in common 
between human beta cells and a mouse insulinoma cell line (MIN6). Additionally, miRquant has 
been used to successfully quantify miRNA and isomiR expression in a wide variety of cell and 
tissue types including MCF-7 cells (discussed in Chapter 5), liver tissue from mice fed a high-fat 
or low-fat diet [16], colon tissue from patients with Crohn's disease [17], and liver tissue from 
patients with hepatitis B and C [18].  
Significant bias has been observed in small RNA sequencing libraries depending on the 
library preparation kit used to prepare the samples [19]. One of the primary determinants of the 
observed bias is the variable efficiency of adapter ligation[12,14,15]. Many types of HTS 
	 5	
libraries require the ligation of fixed adapter sequences to the target RNA/DNA fragment, and 
this step leads to the preferential binding of certain fragments to the adapter sequences[14]. 
This issue is exacerbated in small RNA sequencing due to the fact miRNA species contain a 
single sequenced fragment that encompasses the whole of the sequenced target rather than 
randomly distributed fragments within a larger sequence (as in mRNA-seq). This results in 
individual miRNA species having less diversity at the adapter ligation boundaries than the pool 
of fragments derived from the larger transcripts that are sequenced in mRNA-seq. The lack of 
sequence diversity for a given miRNA species combined with the severity of the adapter ligation 
bias issue leads to certain miRNA species evading capture in most small RNA libraries[19]. 
Recent advances in small RNA library preparation protocols have led to the introduction of a 
protocol that utilizes adapters with degenerate bases at the ligation boundaries. Evaluation of 
this protocol (discussed in Chapter 3) shows that miRNA expression from libraries sequenced 
using this kit produce normalized read counts that most closely match results obtained by RT-
qPCR. Additionally, using this kit allows us to capture miRNA species that we were previously 
unable to observe using the standard Illumina library preparation protocols that use fixed 
adapter sequences. This was particularly critical for our study because the miRNA we found to 
be a key regulator of the cellular response to estrogen, miR-503, is not efficiently captured by 
standard library preparation protocols that use fixed adapter sequences. 
Finally, miRNAs and their isomiRs can repress a large number of mRNA targets [6], but 
our studies have shown us that there exist certain miRNA or isomiRs that target a list or network 
of genes more than expected by chance [20,21]. We term these miRNAs “master regulators” of 
the target gene list / network. Identification of miRNA “master regulators” can be performed 
using a custom target site enrichment algorithm called miRhub (discussed in Chapter 4). To 
prototype the miRhub algorithm we examined genes subject to single nucleotide polymorphisms 
(SNPs) in type 2 diabetes (T2D) patients, which allowed us to uncover an isomiR of miR-375 
that acts as potential master regulator of T2D. Additionally, miRhub has been used successfully 
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in numerous studies in the lab including the identification of miR-29 as a candidate master 
regulator of Foxa2 target genes in the mouse liver [16], the identification of miR-31-5p and miR-
203 as candidate master regulators of genes differentially expressed in the colon of patients 
with Crohn's disease compared to those with non inflammatory bowel diseases [17], and the 
identification of miR-503 as a candidate master regulator of estrogen responsive genes in MCF-
7 cells (discussed in Chapter 5). 
 
1.3 Breast cancer and the estrogen response 
Breast cancer is one of the most prevalent causes of cancer-related death in women 
world-wide[22], and is categorized into at least five molecular subtypes[23]. In a clinical setting, 
these subtypes are defined primarily by a marker for proliferation (Ki67) and the expression of 
three cellular receptors: estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2)[24]. The five most commonly studied molecular 
subtypes, which are luminal A (LA), luminal B (LB), basal-like (BL), HER2-enriched (HER2), and 
normal-like (NL), are clinically relevant in terms of treatment response and are used to inform 
new therapies for breast cancer[25]. Both luminal subtypes express the ER, only LA expresses 
the PR, and the remaining subtypes display little to no expression of either hormone 
receptor[25]. Current recommendations for breast cancer treatment are based on an 
approximation of the molecular subtype using immunohistochemistry on tumor biopsies. In 
essence, tumors expressing hormone receptors are treated with hormone therapies, those 
overexpressing HER2 are treated with anti-HER2 therapies, and those lacking either are treated 
with chemotherapy alone[24]. Subtypes expressing a combination of these features receive a 
combined therapy; for example, ER+/HER2+ tumors (clinically classified as luminal B/HER2+) 
would receive all three therapies [24]. 
By far the most prevalent forms of breast cancer are those that stain positive for 
estrogen receptor-α (ERα)[24]. The estrogen receptor, in particular ERα (encoded by the ESR1 
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gene), has been widely studied in breast cancer [26-28]. ERα binds to estrogen (usually 
estradiol or E2), dimerizes, and translocates to the nucleus where it recruits co-activators or co-
repressors to estrogen response elements (EREs)[28]. Although the estrogen receptor can form 
either ERα and ERβ homodimers, or ERα/ERβ heterodimers, ERα is thought to be the primary 
receptor involved in the estrogen response of both normal and breast cancer cells [29] and 
therefore is the focus of our study. ERα is extensively regulated at the transcriptional, post-
transcriptional and post-translational levels, and its activity is pivotal to both the promotion of 
proliferation and prevention of transformation [30]. 
 
1.3.1 miRNAs in breast cancer 
In breast cancer, several miRNAs have been identified that target and degrade 
ESR1[28], and numerous miRNAs have been identified as potential biomarkers or therapeutic 
targets [31]. At least five miRNAs (miR-22, miR-222, miR-221, miR-18a and miR-206) are both 
repressors of the ESR1 mRNA and regulated by ERα [28]. Post-transcriptional regulation of 
ERα is of significant interest in breast cancer because although ER(-) cancers lack the estrogen 
receptor, many ER(-) tumors still express the ESR1 mRNA without accumulating mature ERα 
protein [32]. One example of the importance of miRNA-mediated regulation in estrogen 
signaling is miR-18a, a miRNA that has been shown to target the ESR1 gene, and is involved in 
a feedback loop in which ligand-bound ERα induces expression of the miR-17-92 cluster (of 
which miR-18a is a member) through activation of c-MYC. Post-maturation, miR-18a represses 
the translation of ESR1 mRNA in breast cancer cells [33]. Additionally, studies have shown that 
this miRNA is more highly expressed in ER(-) breast cancer, leading to the hypothesis that 
altered miR-18a expression may play a role in the loss of ER signaling in breast cancer [28]. 
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1.3.2 Estrogen responsive coding RNAs 
Estrogen regulates the expression of a large number of mRNAs with different functions 
[30,34]. Firstly, estrogen stimulates both proliferation [28] and survival [35] of breast cancer 
cells. One mechanism by which ERα stimulates cell proliferation is through the estrogen-
dependent activation of MAPK [36], while estrogen stimulated survival is mediated in part by the 
induction of the Inhibitor of Apoptosis family member, cIAP2 [35]. Additionally, ERα promotes an 
epithelial phenotype through its interaction with the transcription factors GATA3 and FOXA1, 
both of which are important transcriptional regulators [30,37]. Finally, ERα opposes the 
epithelial to mesenchymal transition (EMT) through down regulation of the transcription factors 
Snail 1 and Snail 2[38]. ER+ tumors are treated with anti-estrogen therapies that inhibit all 
estrogen-mediated signaling. Thus while such treatment may reduce tumor cell mass, it may 
also remove some of the estrogen-mediated safeguards against EMT. 
 
1.4 Dynamic expression of coding and non-coding RNAs in breast cancer 
Recent studies of the dynamics of ERα-mediated transcription in MCF-7 breast cancer 
cells have demonstrated that estrogen treatment induces transcriptional bursts by linking ERα 
transcriptional activity to proteasome-mediated degradation of ERα[39]. However, few studies 
have investigated how estrogen-stimulated regulatory networks change over time [34,40]. 
Additionally, although miRNAs have been profiled at one time point after estrogen stimulation 
[41] and one study investigated the dynamics of both mRNAs and miRNAs in response to 
estrogen [40], there are no sequencing based studies in which matched mRNA and miRNA 
expression has been measured at multiple time points in response to estrogen stimulation. The 
study of regulatory networks is greatly enhanced by the inclusion of temporal data, as it 
expands static interaction diagrams into dynamic models that can uncover complex behaviors, 
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such as the generation of expression thresholds[42], or the existence of stable points that allow 
the cell to maintain expression in the absence of continued stimulation [43]. 
The response of ER+ breast cancer cells to estrogen stimulation is well studied, but the 
matched temporal profile of both mRNAs and miRNAs has not yet been established. This 
system is an excellent model for investigating the regulatory architecture of cells responding to 
cellular signals (in this case the hormone estrogen). Utilizing the tools and techniques that I 
developed and which I have described in Chapters 2-4, I sought to identify both mRNA and 
miRNA species that are both regulated by estrogen stimulation in breast cancer and have a 
potential impact on the regulatory networks critical to the etiology of breast cancer (Chapter 5).  
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CHAPTER 2: QUANTIFICATION OF MIRNAS AND THEIR ISOMIRS FROM HIGH 
THROUGHPUT SEQUENCING1 
 
2.1 Overview 
microRNAs (miRNAs) are small non-coding RNAs that bind to and regulate the stability 
and/or translation of RNA molecules. Next-generation deep sequencing of small RNAs has 
unveiled the complexity of the miRNA transcriptome, which is in large part due to the diversity of 
miRNA sequence variants (“isomiRs”). The miRNA 5’-end sequence, referred to as the “seed” 
region, is a critical determinant of miRNA targeting and function. As such, changes at the 5’-end 
of a miRNA, including shifted start positions, can redirect targeting to a dramatically different set 
of RNAs and alter biological function. miRNA 5’-end diversity remains uncharacterized in beta 
cells. Therefore, we performed deep sequencing of small RNA from mouse insulinoma (MIN6) 
cells (widely used as a surrogate for the study of pancreatic beta cells) and developed a 
bioinformatic analysis pipeline (miRquant) to profile isomiR diversity. Additionally, we applied 
the pipeline to recently published small RNA-seq data from primary human beta cells and whole 
islets and compared the miRNA profiles with that of MIN6. These analyses led to the following 
three key observations:  
(1) The miRNA expression profile in MIN6 cells is highly correlated with those of primary 
human beta cell and whole islet samples.  
																																																								
1 Portions of this chapter were previously published as an article in the journal PLoS ONE. The 
original citation is as follows: Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. Beta Cell 5′-
Shifted isomiRs Are Candidate Regulatory Hubs in Type 2 Diabetes. PLoS ONE; 2013;8: 
e73240. 
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(2) miRNA loci can be classified as either: (a) homogenous – which generate isomiRs with a 
single dominant 5’-start, or (b) heterogeneous – which generate multiple highly 
expressed isomiRs with different 5’-start positions (5’-isomiRs); 
(3) IsomiRs with shifted 5’-start positions (5’-shifted isomiRs) are highly expressed in MIN6, 
primary human beta cells and whole islets, and can be as abundant as their unshifted 
counterparts (5’-reference miRNAs).  
 
2.2 Introduction 
miRNAs are short regulatory RNAs that are processed from variable length primary 
transcripts through consecutive ribonuclease-mediated cleavage events [44,45]. miRNAs guide 
and tether the RNA induced silencing complex (RISC) to specific RNAs in order to regulate their 
stability and/or translation [6]. Numerous studies have identified miRNAs as important 
modulators of a wide variety of biological pathways[46,47]; for example, miR-375-mediated 
gene regulation is critical for both beta cell development and function. [48,49].  
Similar to protein coding genes, miRNAs are present in multiple isoforms, called isomiRs 
[50-52]. IsomiRs are sequence variants, generated from a single miRNA locus, that consist of 
one or both of two types of variations: templated and non-templated [51,53,54](Figure 2.1). 
Templated variants match the genomic sequence, but have differing 5’-start and/or 3’-end 
positions, likely due to processing heterogeneity by Drosha/Dicer [44,45] and/or exonuclease-
mediated nucleotide trimming [55,56]. Non-templated isomiRs are diverged from the genomic 
sequence due to post-transcriptional enzymatic processes that add, remove, or edit specific 
nucleotides[52]. Nucleotide additions are catalyzed by a class of enzymes called ribonucleotidyl 
transferases, which modify miRNAs by covalent addition of nucleotides to the 3’-end [57]. The 
most prevalent form of RNA editing is the adenosine-to-inosine edit, which is mediated by the 
double-stranded RNA adenosine deaminase (ADAR) family of enzymes [58]. 
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Figure 2.1: Sources of isomiR diversity. The top panel illustrates sources of isomiR diversity, 
which stratify into two classes: templated and non-templated variations. As illustrated by the 
bottom panel, an isomiR may contain one or both types of variations, and both templated (e.g. 
5′-shifts) and non-templated (e.g. RNA edits) variations can create an isomiR with an altered 
“seed”. The “seed” region of each isomiR is underlined. 
IsomiRs were initially dismissed as byproducts of technical (e.g. sequencing errors) or 
biological noise [59,60]. However, recent studies have shown that isomiRs interact with the 
RISC and are present in polysomes [61-64], suggesting that they may be biologically relevant. 
Several studies have demonstrated that 3’-non-templated nucleotide additions (3’-NTAs), most 
commonly uridylation or adenylation [11,61,64-68], affect miRNA stability and/or loading onto 
the RISC [52,64,65] and are physiologically regulated [57,69]. Also, several studies have 
identified isomiRs generated by RNA edits at the 5’-end of the miRNA [70-73], referred to as the 
“seed” region, which is a critical determinant of stable miRNA targeting [6]. Modifications to the 
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“seed” region have the potential to redirect a miRNA to a vastly different set of target RNAs, 
thereby potentially altering its biological function [70]. Perhaps the best-studied example of this 
phenomenon is the A-to-I editing of the miR-376 primary transcript leading to the expression of 
a 5’-isomiR of miR-376 with a modified “seed” [70]. The canonical version of miR-376 and its 
“seed”-altered isomiR were shown to have highly distinct target sets [70], highlighting the 
biological importance of 5’-isomiRs.  
5’-isomiRs are not limited to those generated by RNA edits; they can also be produced 
by processing heterogeneity and/or 5’-end nucleotide trimming, which can shift the 5’-start 
positions of miRNAs (Figure 2.1). 5’-shifted isomiRs have been identified in a few recent 
studies[11,61,64,74-76]; however, they are often reported to be lowly expressed [11,61] and 
continue to be perceived as rare [51]. As such, they are often overlooked by deep sequencing 
studies, including those performed in pancreatic beta cells. Because the 5’-end of a miRNA is 
so critical for function, it is of substantial interest to characterize comprehensively the 
prevalence and physiological relevance of miRNA 5’-diversity. 
To that end, we developed an in-house bioinformatic analysis pipeline called miRquant 
to quantify miRNAs and their isomiRs. We applied miRquant to small RNA-seq libraries 
prepared from mouse insulinoma cells (MIN6), which are widely used as a surrogate for 
pancreatic beta cells [77]. Further, we applied miRquant to published small RNA-seq libraries 
from primary human beta cells and whole islets. Strikingly, we found not only that the miRNA 
expression profile in MIN6 cells correlates very well with those of the primary human beta cells 
and islets (r2 > 0.98), but also that 7 highly expressed 5’-shifted isomiRs in MIN6 cells are also 
abundant in human beta cells and whole islet.  
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Figure 2.2: Overview of miRquant alignment pipeline. Trimmed reads are mapped in a tiered 
fashion to the genome. First, reads that map exactly to the genome, and these reads are used 
as a surrogate to define transcriptionally active regions of the genome (upper right). Next, any 
remaining un-mapped reads are allowed to map imperfectly only to the genomic windows 
generated in the previous stage, as opposed to the entire genome, thereby drastically reducing 
the mapable space. One mismatch is allowed in the beginning of the read and up to three 
mismatches are allowed at the 3’-end of the read, depending on length (lower right). An 
example alignment seed set is shown, where zeros mark the locations where mismatches are 
allowed. All reads that map equally well to multiple loci are proportionally assigned to all those 
loci. 
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2.3 Results 
2.3.1 A pipeline for detailed quantification of miRNAs and their isomiRs 
To capture the diversity of expressed miRNAs and their isomiRs, we developed an in-
house bioinformatics pipeline (miRquant) to process and quantify small RNA-seq reads that 
align to both known annotated miRNAs, and potential novel miRNAs (Figure 2.2). miRNA 
sequences can contain several mismatches to the genome due to (1) RNA edits and (2) NTAs. 
To align short reads with many potential mismatches, we utilize a multi-stage alignment 
strategy. First reads are aligned with no mismatches allowed. Next, in a second alignment 
stage, alignments with mismatches are allowed to regions of the genome where other reads 
align perfectly. Finally, miRNAs and their isomiRs can be quantified and sequence variations 
can be cataloged. 
 
miRquant small RNA-sequencing alignment pipeline: 
Step 1: Sequencing reads are trimmed to remove 3’ adapter remnants. 
Small RNAs are typically shorter than the length of reads from high throughput 
sequencing. miRNAs have an average length of 22 nucleotides, and typical HTS reads lengths 
are 50 nucleotides. Therefore, roughly half of the read contains a remnant of the 3’ adapter 
sequence. In order to accurately align the RNA fragment to the genome, the 3’ adapter remnant 
is trimmed using cutAdapt (Preferred parameters: Overlap = 10, number of errors=1). 
Step 2: Align trimmed reads to the reference genome (no mismatches). 
Trimmed reads are aligned to the reference genome using the bowtie algorithm 
(Parameters: -q –a –m 20 –n 0 –e 70). This stage of the pipeline serves two purposes: (1) we 
acquire a best match for every read to the reference genome and (2) we interpret the regions 
surrounding these matches as transcriptionally active. The regions defined by these perfectly 
aligned reads are used to generate a set of genomic windows in which further alignments will be 
attempted.  
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Step 3: Generate library of windows surrounding exact matches. 
To align short reads with several mismatches, we make the simplifying assumption that 
every expressed miRNA will have at least one read that will perfectly align to the genome (no 
edits, or NTAs). To capture miRNA related reads, we define regions surrounding perfectly 
aligned reads as a set of genomic windows. Windows separated by fewer than 65 nucleotides 
are merged as they may represent miRNA precursor loci. Merged windows are further extended 
by 5 nucleotides on either end to capture any non-templated additions. Finally these windows 
are converted to FASTA format.  
Step 4: Align remaining reads to window library (mismatches allowed). 
 Our final alignment stage attempts to align any previously unaligned reads to the newly 
generated FASTA library of genomic windows (with mismatches allowed) using SHRiMP2. 
Specifically, the set of all possible “alignment seeds” containing one mismatch in the body and 
up to three mismatches at the 3’-end (depending on read length) is generated and used to align 
all reads to the genomic windows (Figure 2.2). The number of mismatches allowed at the 3’-end 
(M1) for a read of length L is defined as: M1 = 0 if L < 16, M1 = 1 if 16 ≤ L <19, M1 = 2 if 19 ≤ L ≤ 
23, and M1 = 3 if L > 23. Finally, alignments are scanned and only the best alignments are 
retained. All reads mapping equally well to multiple loci are proportionally assigned to those loci. 
Step 5: Consolidate results and catalog isomiR diversity. 
 All aligned reads (from both stages) are grouped by 5’-start position (5’-isomiRs) and are 
annotated with respect to the 5’-start position of the reference (miRBase r19) miRNA at the 
same locus. For each 5’-isomiR, an overall expression level is reported, and all reads with 
mismatches at the 3’-end are reported as 3’-NTAs (by nucleotide(s) added). Alignments with 
internal mismatches are reported as potential RNA edits. 
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2.3.2 Comparing the miRNA and 5’-isomiR profiles of MIN6, human beta cell, and 
human islet  
To characterize isomiR diversity (Figure 2.1) in mouse insulinoma cells (MIN6), we 
generated small RNA libraries (n=3) and performed deep sequencing on the Illumina HiSeq 
2000 platform (Methods), which yielded ~18 million reads per replicate. After 3’-adaptor 
trimming, on average ~50% of the reads were within the expected size range (16-27 nt) for 
miRNAs. To analyze the small RNA-seq reads further, we developed and implemented an in-
house bioinformatic analysis pipeline for highly sensitive detection and quantitation of isomiRs 
(miRquant; Figure 2.2). We successfully mapped ~92% of the trimmed MIN6 reads in each 
replicate and on average ~75% of the mapped reads corresponded to annotated miRNA loci. 
We also used our pipeline to analyze published small RNA-seq datasets from primary 
human beta cells (n=2) and whole islet (n=1) [78]. These datasets had approximately 41, 33 and 
79 million reads respectively, and in each case more than 80% of the 3’-adaptor trimmed reads 
were within the expected size range (16-27nt) for miRNAs. We successfully mapped ~97% of 
the trimmed reads and on average ~85% of the mapped reads corresponded to annotated 
miRNA loci. 
In each of the datasets, >1,000 distinct mature miRNAs were represented by at least ten 
reads. However, 98% of the miRNA-related reads captured the top ~100-150 mature miRNAs 
depending on the dataset. We refer to these miRNAs as “highly expressed.” To compare 
miRNA profiles across the MIN6 replicates and human samples, we first assembled a list of 
miRNAs that were “highly expressed” in at least one dataset, resulting in 209 distinct mature 
miRNAs produced from 187 unique pre-miRNAs . These 187 pre-miRNAs consisted of:  
(1) 166 pre-miRNAs that generate at most one mature miRNA from each arm of the 
hairpin-like structure (“homogenous loci”), including one locus (pre-miR-5099) that 
produces only a 5’-shifted isomiR (mmu-miR-5099-2); and  
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(2) 21 pre-miRNAs that generate more than one mature miRNA from the same arm 
(“heterogeneous loci”), including one locus (pre-miR-375) that produces one 5’-
reference miRNA and two 5’-shifted isomiRs.   
Among the 209 mature miRNAs, 186 were 5’-reference miRNAs and 23 were 5’-shifted 
isomiRs. The miRNA profiles of each of the MIN6 replicates correlated extremely well with each 
other (r2 ~ 0.99) and, strikingly, also with those of the human beta cells (average r2 = 0.98) and 
whole islets (average r2 = 0.97) (Figure 2.3A). As a control, we also sequenced libraries of small 
RNAs from the mouse liver prepared according to the same protocol and determined that as 
expected the correlation with the MIN6 profile was very poor (r2 < 0.1; data not shown). The 
isomiRs from the heterogeneous loci were distributed across the spectrum of highly expressed 
miRNAs (Figure 2.3B), indicating that the heterogeneous status of a miRNA locus is not merely 
a function of the level of expression. 
Although miRNA expression among these samples was highly correlated overall, such 
as in the case of miR-22-3p or miR-24-1-3p (Figure 2.4A), several miRNAs appeared to be 
specifically or preferentially expressed in either the MIN6 cells or human beta cells/islets (Figure 
2.4A). For example, miR-143-3p and miR-204-5p were 791- and 265-fold more highly 
expressed, respectively, in the human beta cells than in the MIN6 cell line (Figure 2.4A). 
Likewise, miR-93-5p and miR-409-5p were 38- and 85-fold more highly expressed, respectively, 
in MIN6 cells than in human beta cells (Figure 2.4A).  
 
2.3.3 Characterization of beta cell 5’-shifted isomiRs 
Of the 23 highly expressed MIN6 5’-shifted isomiRs, only mmu-miR-5099-2 and mmu-
miR-101b-3p-1 did not have a homologous miRNA in the human samples. Among the remaining 
21, two were in the set of top 20 most highly expressed miRNAs in each of the MIN6 and 
human datasets: miR-375+1 and miR-375-1. Many of the 5’-shifted isomiRs, such as miR-
375+1, miR-375-1, and miR-27b-3p-1, were expressed at similar levels in MIN6, human beta 
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cell, and human islet samples (Figure 2.4B). However, some 5’-shifted isomiRs were 
preferentially associated with either MIN6 or one of the human samples. For example, miR-192-
5p+1 was 22-fold more highly expressed in human beta cells than in MIN6, miR-10a-5p+1 was 
23-fold more highly expressed in human islets than in MIN6, and miR-183-5p+1 was nearly 3-
fold more highly expressed in MIN6 than in human beta cells or islets (Figure 2.4B). These 
differences are likely in part a reflection of the disparities in cellular composition among MIN6 
cells, beta cells, and whole islets. Nevertheless, the overall profile of 5’-shifted isomiRs was 
fairly highly correlated between MIN6 and human beta cells/islets (r2 ~ 0.7).  
To illustrate the potential regulatory impact of these 5’-shifted isomiRs we used 
TargetScan [79] to predict targets for miR-375 and its 5’-shifted isomiRs, miR-375+1 and miR-
375-1. While miR-375 has 390 predicted targets conserved between human and mouse, miR-
375-1 targets has more than twice that many, and strikingly, miR-375+1 has only 14 (Figure 
2.4C). Only eight genes (ELAVL4, HNF1B, NFIX, NPAS3, PAX2, SHOX2, SLC16A2, and 
TSC22D2) have predicted conserved target sites for miR-375 and both of its 5’-shifted isomiRs. 
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Figure 2.3: miRNA and isomiR profiles in MIN6 cells, primary human beta cells and 
human islet. (A) A heatmap is shown depicting the Pearson correlation coefficients of miRNA 
profiles between pairs of samples analyzed in this study. (B) The x-axis depicts highly 
expressed miRNAs ordered from left to right by decreasing maximal expression across all 
samples. The y-axis depicts the Log10 of the average read count per million. Each dot 
represents a miRNA. miRNAs from a homogenous locus (a pre-miRNA that produces only one 
mature miRNA per arm of the hairpin) are in gray. miRNAs from a heterogeneous locus (a pre-
miRNA that produces more than one mature miRNA per arm of the hairpin) are either pink (5′-
reference) or blue (5′-shifted). 
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Figure 2.4: Comparison of 5′-reference miRNA and 5′-shifted isomiR expression levels 
among MIN6 cells, human beta cells, and human islet. (A) The x-axis lists selected 5′-
reference miRNAs in MIN6 (red), human beta cells (green), and human islets (blue). The y-axis 
depicts the Log10 of the average read count per million for each 5′-reference miRNA in each 
sample. (B) The x-axis shows the highly expressed 5′-shifted isomiRs ordered from left to right 
by decreasing fold-difference between primary human beta cells and MIN6 cells. The y-axis 
depicts the average read count per million for each 5′-shifted isomiR. (C) The number of genes 
with at least one conserved target site for miR-375 (gray), miR-375+1 (green), and miR-375-1 
(orange) is shown. All sets are mutually exclusive: for example, a total of 390 genes have 
predicted conserved miR-375 target sites (42 unique to miR-375, 3 shared with miR-375+1 only, 
337 shared with miR-375-1 only, and 8 common to all three). 
 
2.4 Discussion 
In this study we developed the miRquant pipeline to characterize isomiR diversity, and 
applied this method to study isomiR expression in the MIN6 cell line, primary human beta cells 
and islets. We found that (1) the miRNA expression profile in the MIN6 cell line is highly 
correlated with that of the primary human beta cells, (2) miRNA loci can be classified as either 
homogeneous (producing a single highly expressed 5’-isomiR) or heterogeneous (producing 
multiple highly expressed 5’-isomiRs), (3) 5’-shifted isomiRs can be as abundant as their 5’-
reference counterparts, and (4) there are seven 5’-shifted isomiRs highly expressed in MIN6 
cells that are also abundant in human beta cells and islets. Additionally, we identified 10 beta 
cell miRNAs, including three 5’-shifted isomiRs, as candidate regulatory hubs in type 2 diabetes. 
We evaluated several predicted gene targets of our top candidate regulatory hub, miR-29, and 
demonstrated the potential of the 5’-shifted isomiRs miR-375+1 and miR-375-1 to differentially 
regulate gene expression in MIN6 cells. The findings in this study promote the notion that 5’-
shifted isomiRs are prevalent and potentially impact disease, thus widening the panoramic view 
of the functional miRNA-ome. 
 
2.5 Materials and methods 
Small RNA-seq datasets 
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MIN6 cells were cultured in high glucose (25mM) DMEM (Sigma) supplemented with 
10% heat-inactivated fetal bovine serum. Cells were lysed and total RNA was extracted using 
the Norgen total RNA purification kit. RNA quality was assessed by Agilent 2100 Bioanalyzer, 
and only very high quality samples with RNA Integrity Number (RIN) above 9.0 were considered 
further. Small RNA libraries (three biological replicates) were generated using the Illumina 
TruSeq small RNA library preparation kit. These libraries were then sequenced on the Illumina 
HiSeq platform. Small RNA-seq data are available in the GEO database (submission in 
progress). Sequencing of small RNAs from mouse liver was conducted as well, in accordance 
with the protocol described above. 
Human primary cell data: Primary beta cell and whole islet small RNA-seq datasets were 
obtained from GEO (GSE47720:[78]). This study included two libraries of beta cells 
(GSM1155397 and GSM1155398) and one whole islet sample (GSM1155395) that were 
prepared with the Illumina TruSeq protocol and sequenced on the Illumina HiSeq 2000 platform. 
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CHAPTER 3: ADDRESSING BIAS IN SMALL RNA LIBRARY PREPARATION FOR 
SEQUENCING: A NEW PROTOCOL RECOVERS MICRORNAS THAT EVADE CAPTURE BY 
CURRENT METHODS2 
 
3.1 Overview 
Recent advances in sequencing technology have helped unveil the unexpected 
complexity and diversity of small RNAs. A critical step in small RNA library preparation for 
sequencing is the ligation of adapter sequences to both the 5’ and 3’ ends of small RNAs. 
Studies have shown that adapter ligation introduces a significant but widely unappreciated bias 
in the results of high-throughput small RNA sequencing. We show that due to this bias the two 
widely used Illumina library preparation protocols produce strikingly different microRNA (miRNA) 
expression profiles in the same batch of cells. There are 102 highly expressed miRNAs that are 
>5-fold differentially detected and some miRNAs, such as miR-24-3p, are over 30-fold 
differentially detected. While some level of bias in library preparation is not surprising, the 
apparent massive differential bias between these two widely used adapter sets is not well 
appreciated. In an attempt to mitigate this bias, the new Bioo Scientific NEXTflex V2 protocol 
utilizes a pool of adapters with random nucleotides at the ligation boundary. We show that this 
protocol is able to detect robustly several miRNAs that evade capture by the Illumina-based 
methods. While these analyses do not indicate a definitive gold standard for small RNA library 
preparation, the results of the NEXTflex protocol do correlate best with RT-qPCR. As 
increasingly more laboratories seek to study small RNAs, researchers should be aware of the 
																																																								
2 This chapter was previously published as an article in the journal Frontiers in Genetics. The 
original citation is as follows: Baran-Gale J, et al. Addressing Bias in Small RNA Library 
Preparation for Sequencing: A New Protocol Recovers MicroRNAs that Evade Capture by 
Current Methods. Front Gene. 2015;6: 352. 
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extent to which the results may differ with different protocols, and should make an informed 
decision about the protocol that best fits their study. 
 
3.2 Introduction 
Small RNAs, such as microRNAs (miRNAs), are important regulators of gene expression 
in a wide variety of normal biological and pathological processes[6,80]. Numerous technologies, 
including quantitative PCR (qPCR), microarray, and deep sequencing, are presently in use for 
high-throughput miRNA profiling[53,81,82]. Though each of these methods has both 
advantages and limitations, deep sequencing has emerged as the gold standard for discovery 
and quantification of miRNAs, particularly for those that are of low abundance. Numerous small 
RNA library preparation protocols are currently available, including kits from Illumina, Applied 
Biosystems (ABI) SOLiD, New England BioLabs (NEB), and TriLink Biotechnologies (Table 3.1). 
Recent studies have demonstrated that each of these technologies harbors different limitations 
that lead to variable biases[83,84]. 
Table 3.1: Current small RNA library preparation protocols and features. The protocols 
discussed in this study are in boldface font. 
Company Protocol Adapters Adapter dimer 
removal 
RNA input 
recommendations 
Illumina V1.5 Fixed None 1-10 µg total RNA 
Illumina TruSeq Fixed None 1 µg total RNA 
Applied 
BioSystems 
SOLiD small 
RNA expression 
kit 
Degenerate 
hybridization 
None 0.25-1 µg total RNA 
Bioo Scientific NEXTflex V2 Degenerate Excess 3’ 
adapter removal 
1-10 µg total RNA 
NEB NEBNext Fixed Excess 3’ 
adapter removal 
0.1-1 µg total RNA 
TriLink 
Biotechnologies 
CleanTag Fixed Chemically 
modified 
adapters 
1 ng -1 µg total RNA 
SeqMatic TailorMix 
miRNA V2 
Fixed Advanced gel 
extraction 
> 10 ng total RNA 
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A critical step in the preparation of a small RNA library for deep sequencing is the 
ligation of adapter sequences to both ends of small RNAs. These adapters provide the template 
for primer-based reverse transcription, amplification, and sequencing. The efficiency of adapter 
ligation to small RNAs is thought to depend on the adapter sequence, the ligase, and the 
nucleotide composition and secondary structures of the small RNAs[12-15]. Differences in 
adapter ligation efficiency among available protocols can drastically alter the perceived 
abundance of individual miRNAs. 
Currently, the most widely used library preparation kits are those provided by Illumina. 
Illumina introduced the v1.5 small RNA library preparation method in February 2009 and the 
TruSeq method in November 2010. Because one critical difference between these methods is 
the adapter sequences, some level of differential bias between these two methods is expected. 
However, the extent of the bias has not been evaluated previously and could be important for 
guiding accurate comparison of miRNA expression results between these two methods. 
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Figure 3.1: Key differences among different commercially available library preparation 
kits for small RNA sequencing. Some of the innovations in small RNA library preparation are 
highlighted here. First, current kits either used fixed adapter sequences or they introduce 
degenerate bases to both the 3’ and 5’ ligation boundary to improve adapter ligation efficiency. 
Second, adapter dimers can be generated causing a portion of sequenced reads to contain no 
insert. These dimers can be blocked or removed, thus increasing effective sequencing depth. 
Note: orange boxes indicating degenerate bases are not depicted in the adapter dimer graphic 
for the sake of simplicity. 
To address this bias, a few new library preparation methods have been proposed. For 
example, one new protocol called NEXTflex V2 from Bioo Scientific uses a pool of adapters, 
each with random nucleotides (degenerate bases) at the ligation boundary (Figure 3.1). The 
idea behind this strategy is to increase the diversity of adapter sequences thereby increasing 
the chance that any given miRNA will be able to ligate efficiently, and thus mitigating the overall 
bias inherent to protocols that use only one set of adapters. As another example, a recent 
study[12] uses a 5’ adapter with a short subsequence that is fully complementary to a region 
within the 3’ adapter. The intent of this method is to encourage all ligated miRNAs to form the 
same circular RNA structure and thus mitigate structure-based bias across miRNAs. 
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Another important issue for small RNA library preparation is the formation of adapter 
dimers (Figure 3.1). An abundance of adapter dimers in small RNA libraries can lead to 
sequencing a substantial number of reads with no miRNA insert, thus effectively reducing the 
proportion of informative sequencing reads[85]. Currently available library preparation kits either 
(1) fail to address this issue or suggest more precise gel cutting to avoid the adapter dimer 
band, (2) use some method of eliminating excess 3’ adapter prior to the 5’ adapter ligation step, 
or (3) use chemically modified adapters that inhibit the formation of adapter dimers (Figure 3.1). 
Kits that address the issue of adapter dimers can typically produce high-quality results with a 
lower abundance of input RNA. As the field moves toward sequencing of sub-populations of 
cells or single cells, the adapter dimer issue will become increasingly important.  
In this study, we directly compare the small RNA sequencing results between Illumina 
v1.5 and TruSeq. We also perform the sequencing on two different Illumina platforms (GAIIx 
and HiSeq) and at two different sequencing centers (UNC and NIH). While we expected some 
level of bias in the library preparation, the apparent extensive differential bias between these 
two widely used Illumina adapter sets is striking and not reported previously. For example, 50 
highly expressed miRNA species are >10-fold differentially detected between v1.5 and TruSeq. 
This finding serves as an important caution, particularly to laboratories/facilities that used v1.5 
but are now transitioning to the newer protocol. Finally, we compare these results to a library 
generated by a new protocol from Bioo Scientific that seeks to combat both adapter ligation bias 
and excessive adapter dimer formation. We show that this new protocol is able to detect 
miRNAs that evade capture by the more commonly used Illumina protocols, and also produces 
miRNA expression counts that are highly correlated with measurements acquired by RT-qPCR. 
The findings of this study add to the growing body of literature on bias in small RNA sequencing 
that merits continued investigation, particularly with regard to the development of strategies for 
bias remediation and improved miRNA quantification. 
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3.3 Results 
We isolated RNA from a widely-used pancreatic beta-cell-like cell line (MIN6) and 
performed small RNA-seq using four different methods: (1) Illumina v1.5 library preparation 
sequenced on GAIIx platform (v1.5-GAIIx), (2) Illumina TruSeq library preparation sequenced 
on GAIIx platform (TS-GAIIx), (3) Illumina TruSeq library preparation sequenced on HiSeq 
platform (TS-HiSeq) and (4) Bioo Scientific NEXTflex V2 library preparation sequenced on the 
HiSeq platform (NF-HiSeq). TS-GAIIx and v1.5GAIIx were carried out at the NIH Intramural 
Sequencing Center (NISC) on June 25th, 2013; TS-HiSeq was performed at the UNC High 
throughout Sequencing Facility (HTSF) on June 6th, 2013; and NF-HiSeq was performed at the 
Genome Sequencing Facility (GSF) at Greehey Children’s Cancer Research Institute (GCCRI) 
in University of Texas Health Science Center at San Antonio (UTHSCSA) on March 24th, 2015. 
Three replicate small RNA libraries were generated for each of the first three methods, and one 
replicate was generated for the fourth method, yielding a total of ten small RNA-seq datasets. 
The NEXTflex library was prepared from the same RNA that was used to prepare one of the 
TruSeq libraries. 
We used our previously published bioinformatic pipeline[20] to analyze the small RNA-
seq reads in each dataset. The total number of reads across the ten datasets range from ~17 
million to ~29 million. In each of the datasets, >70% of the alignable reads map to annotated 
miRNAs and >1000 distinct mature miRNAs are represented by at least ten reads. Among these 
miRNAs, 358 have a relative expression of at least 100 reads per million mapped reads 
(RPMM) in at least one library. We refer to these miRNAs as “highly expressed.” To compare 
miRNA expression profiles across datasets, we correlated the expression profiles of these 
abundant miRNAs across all ten datasets. 
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Figure 3.2: Comparison of miRNA expression profiles between two different Illumina 
library preparation protocols reveals massive differential bias. A comparison of the 
following four methods is shown: Illumina v1.5 library preparation sequenced on GAIIx platform 
(v1.5_GAIIx), Illumina TruSeq library preparation sequenced on GAIIx platform (TS_GAIIx), 
Illumina TruSeq library preparation sequenced on HiSeq platform (TS_HiSeq) and Bioo 
Scientific NEXTflexV2 library preparation sequenced on the HiSeq platform (NF-HiSeq). Three 
biological replicate small RNA libraries were generated for each of the first three methods and 
one replicate was generated for the NF-HiSeq method. (A) Correlation of miRNA profiles 
between each pair of datasets (correlation values were calculated by Pearson’s metric). Similar 
results were obtained with Spearman’s correlation coefficient, rho (data not shown). White and 
blue colors indicate strongest and weakest correlation, respectively. (B) miRNA expression 
profiles across all ten samples. Hierarchical clustering was used to identify samples with closely 
related expression profiles. Expression is represented as z-score, indicating the number of 
standard deviations below (purple) or above (orange) the mean across all ten libraries. Both (A) 
and (B) used only the set of miRNAs identified as “highly expressed” (n=358). 
The miRNA expression profiles from biological replicates within each method are very 
highly correlated (average pairwise r2 > 0.99), clearly demonstrating that both the method of 
library preparation and the sequencing platform yield exceptionally reproducible results (Figure 
3.2A). Furthermore, we also observe a very strong correlation (average pairwise r2 > 0.86) 
among TS-GAIIx and TS-HiSeq samples, but substantially lower correlation (average pairwise r2 
~ 0.43) among TS-GAIIx (or TS-HiSeq) and v1.5-GAIIx samples (Figure 3.2A). These results 
indicate that neither sequencing platform (GAIIx vs. HiSeq) nor sequencing facility (UNC vs. 
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NIH) is a major contributor to technical variation, but that the method of library preparation (TS 
vs. v1.5) is a significant factor (Figure 3.2B). 
Only 7 out of the 358 highly expressed miRNAs included in the correlation analysis are 
>10-fold differentially detected between TS-GAIIx and TS-HiSeq (Figure 3.3A, Supplementary 
Figure 3.1). Moreover, most of these differentially detected miRNAs are on the lower end of the 
expression spectrum. In stark contrast, when comparing TS-GAIIx with v1.5-GAIIx, 50 miRNAs 
are >10-fold differentially detected and 102 are >5-fold differentially detected (Figure 3.3B). 
Strikingly, ~80% (n=40/50) of the former and ~74% (n=75/102) of the latter set of miRNAs are 
present at greater abundance in the samples prepared by v1.5 compared to the samples 
prepared by TruSeq (Figure 3.3B). These miRNAs include several that are known regulators of 
beta cell development and function, including miR-24-3p[86], miR-29b-3p[87], and miR-200c-
3p[88], which are ~36-fold, ~31-fold, and ~13-fold more highly detected in the samples prepared 
by v1.5, respectively. miR-24-3p is among the ten most highly expressed miRNAs in MIN6 cells 
according to v1.5, but is consistently not even in the top hundred according to TruSeq. It is 
worth noting that despite the overall bias toward higher miRNA expression levels in samples 
prepared by v1.5, a few miRNAs are more highly detected in samples prepared by TruSeq 
(Figure 3.3B). For example, miR-26a-5p, which is known to have functional relevance in the 
beta cell[89], is among the ten most highly expressed miRNAs in MIN6 cells according to 
TruSeq, but is scarcely in the top fifty according to v1.5.  
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Figure 3.3: Fifty of the most abundant miRNAs are greater than ten-fold differentially 
detected between Illumina v1.5 and TruSeq. (A) Comparison of relative expression levels of 
miRNAs in MIN6 (n=358) between the GAIIx and HiSeq sequencing platforms with libraries 
prepared by TruSeq (TS) is shown. Each data point represents the average relative expression 
level for an individual miRNA across three biological replicates. (B) Comparison of relative 
expression levels of miRNAs in MIN6 (n=358) between the v1.5 and TruSeq (TS) library 
preparation methods is shown. Each data point represents the average relative expression level 
for an individual miRNA across three biological replicates. (C-D) Comparison of relative 
expression levels of miRNAs in MIN6 (n=358, (C)) and mouse liver (n=178, (D)) between the 
TruSeq (TS) and NEXTflex (NF) library preparation methods is shown. Each data point 
represents the average relative expression level for an individual miRNA across three biological 
replicates (A-B), or one biological replicate (C-D). Relative miRNA expression levels were 
calculated according to the following: log10(mean(miRNA RPMM)), where RPMM is reads per 
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million mapped reads. Pearson correlation values are displayed in red text within each panel, 
and grey dashed lines denote 10-fold differential expression. 
We also used the new Bioo Scientific NEXTflex V2 protocol to prepare and sequence 
another small RNA library (NF-HiSeq-6) from the same MIN6 RNA that we had used previously 
for the preparation of a library by TruSeq (TS-HiSeq-6). The miRNA expression profiles 
produced by the two different library preparation methods are very poorly correlated (r2 ~ 0.1; 
Figure 3.2A). The miRNA profile produced by NEXTflex V2 is completely different from that of 
Illumina v1.5 as well (Figure 3.2A-B). A total of 75 out of the 358 highly expressed miRNAs, 
including several with important functions in pancreatic beta cells, are >10-fold differentially 
detected between TS-HiSeq and NF-HiSeq (Figure 3.3C). For example, the miR-7 family of 
miRNAs, which regulates insulin secretion in beta cells[90], evades detection by the Illumina 
library preparation methods but is robustly detected by the NEXTflex V2 protocol. Strikingly, 
miR-7a-3p is ~670-fold more highly detected by NEXTflex V2 than by TruSeq, and ~50-fold 
more highly detected by NEXTflex V2 than by v1.5. Other miRNAs implicated in the control of 
beta cell function such as let-7b-5p[87,91,92] and miR-24-3p[86] are ~19-fold and ~15-fold more 
highly detected by NEXTflex V2 than by TruSeq, respectively. It is worth noting that not all 
miRNAs are more highly detected by the NEXTflex V2 method. For example, miR-375-3p 
(another miRNA critical to beta cell function [48,49]) is detected at levels ~6-fold lower by 
NEXTflex V2 than by TruSeq, although it is still identified as one of the most highly expressed 
miRNAs.  
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Figure 3.4: Measurements by quantitative PCR are best correlated with NEXTflex V2. (A) 
Comparison of relative expression levels of four miRNAs (miR-24-3p, miR-27b-3p, miR-29a-3p, 
and miR-375-3p) across five different methods of miRNA detection is shown. (B) Regression 
analysis of the relative expression of four miRNAs for each pair of detection methods is shown. 
The linear regression line is shown below the diagonal and the linear model parameters are 
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shown above the diagonal. miRNA expression levels were normalized to miR-30e-5p, which 
represents a housekeeping miRNA due to its invariance and robust expression across most 
datasets. Linear model parameters: α = intercept, β = coefficient, σ2 = squared residual error, R2 
= fraction of variance explained by model. 
To test whether the differences in miRNA expression profiles between TruSeq and 
NEXTflex V2 library preparation methods are unique to MIN6 or cell culture, we repeated the 
analysis with RNA from mouse liver tissue. Specifically, we prepared two separate small RNA 
libraries, using the TruSeq and NEXTflex V2 protocols, from the same mouse liver RNA and 
then performed sequencing on the HiSeq platform. Out of the 178 highly expressed miRNAs in 
the mouse liver, 40 were > 10-fold differentially detected between the TS-HiSeq-ML and NF-
HiSeq-ML libraries (Figure 3.3D). Included in this list is miR-122, which has a critical role in liver 
biology and disease[93,94]. This miRNA is detected ~ 31-fold more highly with NEXTflex V2 
protocol. In sum, ~20% of highly detected miRNAs are >10-fold differentially detected between 
the two protocols in both cell lines (MIN6) and primary tissue (mouse liver).  
Finally, we selected five miRNAs highly expressed in MIN6 cells, miR-129-5p, miR-24-
3p, miR-27b-3p, miR-29a-3p, and miR-375-3p for quantification by TaqMan-based real time 
reverse transcriptase quantitative PCR (RT-qPCR) (Figure 3.4A). To facilitate a comparison of 
the findings between RT-qPCR and the sequencing methods, we normalized the expression 
levels of each miRNA to that of miR-30e-5p, which is highly expressed and among the least 
variable across the ten small RNA-seq datasets. The sequencing method that the RT-qPCR 
results more closely resemble depends on the miRNA. For example, qPCR-based expression 
for miR-24-3p best matches that of v1.5, whereas for miR-27b-3p it best matches that of 
NEXTflex V2. We next generated a mathematical model to describe the linear relationship in 
miRNA expression between each pair of miRNA detection methods (Figure 3.4B). The residual 
error values (σ2) are by far the lowest for the model relating RT-qPCR and NEXTflex V2, 
indicating that these two methods are the best correlated. As RT-qPCR experiments are not 
without their own biases, it is important to note that these data do not prove definitively that 
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NEXTflex V2 is the most accurate library preparation protocol. However, the data do suggest 
that the NEXTflex V2 protocol is indeed mitigating the adapter ligation bias inherent to the other 
protocols. 
 
3.4 Discussion 
The presence of bias in small RNA profiling is well established in the literature[13,95-97]. 
Differential bias across various expression platforms (e.g., microarray, qPCR, sequencing) and 
sequencing technologies (e.g., Illumina, ABI SOLiD, 454 Life Sciences) has also been 
demonstrated[83,84,98]. However, no study has focused on different library preparation 
methods within the same sequencing technology. Here we compare two of the most popular 
methods from Illumina (v1.5 and TruSeq). The results of our study point to a massive differential 
miRNA detection bias between these two library preparation methods. This finding was 
independent of the sequencing center (NIH, UNC) and sequencing platform (GAIIx, HiSeq). 
While some level of bias in library preparation is not surprising, the apparent extensive 
differential bias between these two widely used adapter sets is striking and not well appreciated 
(for example, miR-24-3p was detected very highly in the v1.5 libraries but was almost 
nonexistent in the TruSeq libraries). 
Although we believe the extent of the bias remains poorly appreciated among many 
small RNA researchers, this bias has been investigated in a few studies, which together 
conclude that ligation efficiency is strongly affected by the co-fold structure of the target RNA 
and the adapter. In 2011, a study by Van Nieuwerburgh et al. demonstrated that sequencing of 
identical samples prepared with different barcodes at the 5’ ligation boundary led to poor 
reproducibility, in contrast to methods in which the barcode is embedded within the adapter itself 
(such as TruSeq). This finding suggests that sequence diversity at the ligation boundaries could 
lead to variable efficiency of adapter ligation, which in turn would result in significant but 
artefactual effects on miRNA detection and quantification. A subsequent study by Jayaprakash 
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et al. provided further support for this finding, as they showed that certain miRNA species could 
be captured effectively only using a scheme that by introducing random bases at the ligation 
boundary. Specifically, this study concluded that introducing two random bases at both the 5’ 
and 3’ ligation boundaries could capture most miRNA species, but that at least one miRNA 
(miR-106b) required four random bases at the 5’ ligation boundary in order to be captured 
efficiently. Other studies (Hafner et al., 2011; Sorefan et al., 2012; Zhuang et al., 2012; Fuchs et 
al., 2015) have investigated the contribution of RNA structure to the adapter ligation bias issue. 
Sorefan et al. found that the introduction of four degenerate bases to both the 3’ and 5’ ligation 
boundaries increased the diversity of structures produced by the adapter and target sequence, 
and thereby reduced adapter ligation bias. Zhuang et al. showed that certain RNA/adapter co-
fold structures are preferred by a variety of T4 RNA ligases, but observed no sequence bias. 
Together these studies suggest that introducing degenerate bases to both ligation boundaries 
introduces both sequence and structural diversity that improves adapter ligation likely by 
introducing favored RNA/adapter co-fold structures. 
Very recently, several new commercially available small RNA library preparation 
protocols have been introduced. Of these new methods, only the Bioo Scientific NEXTflex V2 
protocol also addresses the important issue of adapter dimer formation. In our studies, we found 
that NEXTflex V2 is able to detect robustly several functionally important miRNAs that partially 
or completely evade detection by the widely used Illumina library preparation protocols. A 
prominent example of this in MIN6 cells is miR-7a-3p, which plays a critical role in beta cell 
function. Moreover, we show that miRNA expression levels according to NEXTflex V2 are very 
highly correlated with RT-qPCR measurements. While we cannot say that the results of the 
NEXTflex V2 method accurately represents the “absolute” expression levels of miRNAs, the 
results of our analysis lead us to suggest that this protocol provides the least biased measure of 
miRNA expression among the tested methods.  
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It is important to note that our study does not suggest that one method of library 
preparation is necessarily always more reliable or accurate for miRNA detection than the other. 
Because the ligation efficiencies of different adapter sequences may differ based on features 
that vary across miRNAs, such as nucleotide sequence, chemical modification, and secondary 
structure[13,84,99], care must be taken when using methods that utilize fixed adapter 
sequences. As the factors that control the differential biases between adapter sets continue to 
be investigated, we expect to see continued innovation in small RNA library preparation 
protocols. Researchers seeking to ameliorate the influence of adapter ligation biases on miRNA 
expression levels can consider using protocols that utilize degenerate bases at the adapter 
ligation boundaries (Table 3.1). No one protocol fits every experiment; for example, experiments 
with limited input RNA are better off selecting protocols optimized for such samples regardless 
of adapter bias considerations.  
As increasingly more laboratories begin sequencing small RNAs, researchers should be 
aware of the extent to which the results may differ from previously published results (depending 
on the protocol used). We strongly caution researchers against merging together small RNA-
seq data generated from different adapter sequences. Also, in any standard small RNA-seq 
study in which only one adapter set is used for library preparation, one should be aware of the 
potential pitfalls of applying arbitrary cutoffs based on expression (such as “top 100 detected”) 
to identify miRNAs for further functional analysis, because some miRNAs that appear lowly 
expressed could be inefficiently detected for purely technical reasons (such as miR-24-3p in the 
TruSeq datasets presented in this study). In general, we recommend against using small RNA-
seq data to make calls on the “absolute” levels of miRNAs, unless additional precaution has 
been taken to substantially mitigate the biases discussed here. Despite these issues, deep 
sequencing is still an extremely valuable method for de novo discovery of isomiRs and novel 
small RNAs, as well as for studying relative miRNA expression changes across different 
conditions or time points. 
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3.5 Materials and Methods 
Sequencing and bioinformatic analysis 
Mouse insulinoma (MIN6) cells were cultured as previously described[20]. Cells were 
lysed and RNA was isolated using either the Norgen (Ontario, Canada) Total RNA Purification 
Kit (UNC) or TRIzol-mediated extraction (NIH). Only samples with an RNA Integrity Number 
(RIN) of 8 or higher, as measured by Agilent (Santa Clara, CA) Bioanalyzer 2100, were 
considered for further analysis. Small RNA libraries were generated using either the Illumina 
v1.5 protocol or the Illumina TruSeq protocol. Single-end sequencing was performed on either 
the Illumina GAIIx or Illumina HiSeq 2000 platforms. One library was also generated using the 
Bioo Scientific NEXTflex V2 protocol. For libraries generated with either of the Illumina 
protocols, small RNA-seq reads were trimmed using cutAdapt (-O 10 –e 0.1) to remove 
remnants of the 3’-adapter sequence. For the library generated with the NEXTflex protocol, the 
first 4 and last 4 nucleotides of small RNA-seq reads were trimmed to remove the degenerate 
nucleotides in the adapters. Subsequent mapping of trimmed reads to the mouse genome and 
miRNA/isomiR quantification were performed exactly as previously described[20]. 
A 9 week old C57BL/6J female mouse was purchased from Jackson Laboratories (Bar 
Harbor, ME) as part of a cohort of control mice for another study. This mouse was maintained 
on a 12 hr light/dark cycle with access to a standard chow diet and H2O ad libitum. After a 10 
day acclimation period, the control animal was weighed and injected via tail vein with RNase-
free sterile saline (Bioo Scientific; Austin, TX). Seven days after dosing with saline, the animal 
was fasted (overnight), sacrificed by cervical dislocation without anesthesia and organs were 
collected. The liver was flash frozen in liquid nitrogen and stored at −80°C until RNA was 
extracted using the Norgen (Ontario, Canada) Total RNA Purification kit. Libraries were 
generated using either the Illumina TruSeq or Bioo Scientific NEXTflex V2 protocols. All animal 
work was performed in accordance with the Public Health Service Policy on Humane Care and 
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Use of Laboratory Animals, and all studies were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of North Carolina at Chapel Hill.  
Real time quantitative PCR analysis and linear regression 
MIN6 cells were cultured and lysed as above and RNA was isolated using the Norgen 
Total RNA Purification Kit. Complementary DNA (cDNA) was synthesized using the TaqMan 
miRNA Reverse Transcription kit (Applied Biosystems; Grand Island, NY) according to the 
manufacturer’s instructions. Real-time PCR amplification was performed using TaqMan miRNA 
assays in TaqMan Universal PCR Master Mix on a BioRad CFX96 Touch Real Time PCR 
Detection system (Bio-Rad Laboratories, Inc., Richmond, CA). Reactions were performed in 
triplicate using U6 as the internal control. miRNA levels were expressed as relative quantitative 
values, which represent fold differences relative to miR-30e-5p (a miRNA we found to be among 
the least variable in expression across most library preparation protocols). All TaqMan assays 
used in this study where purchased from Applied Biosystems, Inc. (Grand Island, NY) and 
include: mmu-miR-24-3p (4427975-000402), mmu-miR-27b-3p (4427975-000409), mmu-miR-
29a-3p (4427975-002112), mmu-miR-375-3p (4427975-000564), miR-30e-5p (4427975-
002223), and U6 (4427975-001973). 
Linear regression was used to examine the relationship among different miRNA 
detection methods (RT-qPCR, Illumina V1.5, Illumina TruSeq and Bioo Scientific NEXTflex V2) 
in terms of the expression levels of five miRNAs (miR-129-5p, miR-24-3p, miR-27b-3p, miR-
29a-3p, and miR-375-3p). For this analysis the expression level of each miRNA was normalized 
to that of miR-30e-5p (a miRNA we found to be among the least variable in expression across 
most library methods). A linear model was created in which the relative expression as measured 
by method Y (REY) was modeled as a function of the relative expression as measured by 
method X (REX). In this model (REY = α + β * REX + ε), the term α represents the estimated 
expression level using method Y when the expression level is 0 using method X, β represents 
the weight applied to the expression as measured by method X, and ε represents the random 
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error in the model. To assess the model fit, two additional factors are computed and shown: R2 
(the fraction of variance that is explained by the model) and σ2 (the estimated variance of the 
random error, ε). 
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Supplemental Figure 3.1: Pairwise differential detection of miRNAs in all 10 libraries. 
(Green) Pairwise comparison of relative expression levels of miRNAs between v1.5 and TruSeq 
libraries. (Orange) Pairwise comparison of relative expression levels of miRNAs between 
TruSeq libraries sequenced on either the GAIIx or HiSeq. (Purple) Pairwise comparison of 
relative expression levels of miRNAs between NEXTflex and TruSeq libraries. Relative miRNA 
expression levels were calculated according to the following: log10(miRNA RPMM), where 
RPMM is reads per million mapped reads. Pearson correlation and p-values are displayed in the 
upper triangle, and correlation plots on the lower triangle. 
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CHAPTER 4: IDENTIFYING MIRNA “MASTER REGULATORS” THROUGH TARGET SITE 
ENRICHMENT3 
 
4.1 Overview 
MicroRNAs (miRNAs) act as post-transcriptional repressors of gene expression by 
binding in a reverse complementary fashion to target sites typically within the 3’-UTR of mRNAs. 
The 5’-end of the miRNA sequence, called the “seed region” (nucleotides 2-8), plays a critical 
role in miRNA target recognition. Strong pairing between the “seed region” of the miRNA and 
target sites within the 3’-UTR of mRNAs is correlated with increased miRNA-mediated 
repression of a target mRNA [79]. Families of miRNAs with the same “seed” sequences share 
many of the same targets, and each miRNA family targets many mRNAs. To identify miRNA 
families that are candidates to regulate a set of gene, we developed a target site enrichment 
algorithm called miRhub. The miRhub algorithm identifies miRNA families that are predicted to 
target a gene list or network more than would be expected by chance.  
Among the most highly expressed beta cell miRNAs (n=209; identified in Chapter 2), we 
identified 10 as candidate regulatory hubs in a type 2 diabetes (T2D) gene network. The most 
significant candidate hub was miR-29, which we demonstrated regulates the mRNA levels of 
several genes critical to beta cell function and implicated in T2D (Slc16a1, Camk1d, Jazf1, and 
Glis3). Further studies in the lab have confirmed that miR-29 is indeed an important regulator of 
pathways in diabetes in part by fine-tuning Foxa2 activated lipid metabolism genes in the liver 
[16,21]. In the beta cell, three of the candidate miRNA hubs were novel 5’-shifted isomiRs: miR-																																																								
3 Portions of this chapter were previously published as an article in the journal PLoS ONE. The 
original citation is as follows: Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. Beta Cell 5′-
Shifted isomiRs Are Candidate Regulatory Hubs in Type 2 Diabetes. PLoS ONE; 2013;8: 
e73240. 
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375+1, miR-375-1 and miR-183-5p+1. Although the canonical form of miR-375 is well-studied in 
the beta cell, the shifted forms have not been identified previously. We showed by in silico target 
prediction and in vitro transfection studies that both miR-375+1 and miR-375-1 are likely to 
target an overlapping, but distinct suite of beta cell genes compared to canonical miR-375. In 
summary, this study characterizes the isomiR profile in beta cells for the first time, and also 
highlights the potential functional relevance of 5’-shifted isomiRs to T2D. 
 
4.2 Introduction 
miRNAs bind to target sites typically within the 3’-UTR of mRNAs and tether the RNA 
Induced Silencing Complex (RISC) to the mRNA, leading to the translational inhibition of the 
mRNA or its degradation [6]. The “seed” region of the miRNA (nucleotides 2-8) is the most 
critical determinant of miRNA targeting potential. In fact, the level of post-transcriptional 
repression mediated by a miRNA on its target is correlated to the degree of complementarity 
between the miRNA “seed” region and the target mRNA [79].  
Utilizing the same data from Chapter 2, we sought to identify highly expressed beta cell 
miRNAs and isomiRs that are predicted to target genes related to Type 2 Diabetes (T2D) more 
than is expected by chance. Accordingly, we developed a miRNA target site enrichment 
algorithm called miRhub, and applied it to genes implicated in T2D and related conditions. 
Finally, using the miRhub algorithm, we identified ten highly expressed beta cell miRNAs, 
including three 5’-shifted isomiRs, as significant candidate regulatory hubs in a T2D gene 
network. 
 
4.3 Results 
4.3.1 miRNA regulatory hubs enrichment algorithm 
A miRNA acts as a “master regulator” of a gene network if it is predicted to target genes 
within that network more than is expected by chance. To identify miRNAs master regulators we 
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have developed a target enrichment algorithm titled miRhub. The miRhub algorithm computes 
the predicted impact for each miRNA in a set (typically those miRNAs that are highly expressed 
in a particular cell type) on a network of genes (typically those relevant to the study of a disease 
relevant in that cell type). The algorithm utilizes a Monte Carlo simulation to compare an impact 
score in the target gene network to scores from randomly generated networks with similar 
characteristics. miRNAs that are predicted to target the input gene network more strongly than 
the random networks are candidate master regulators of the input gene network.  
First, the “seed”-based target prediction algorithm TargetScanS 5.2[79] is used to 
determine the number of predicted conserved targets among the human genes in the target 
network for each miRNA under test. Each predicted miRNA – gene interaction is assigned a 
score based on the strength of the “seed” match, the level of conservation of the target site, and 
the clustering of target sites within that gene’s 3’-UTR. Additionally, the score for each gene is 
weighted according to the number of high-confidence protein-protein interactions reported in the 
STRING 9.0 database[100]. Finally, for each miRNA, the final an average targeting score is 
calculated for all genes in the network. In order to generate a background distribution of the 
predicted targeting scores for each miRNA, we repeated this procedure 30,000 times, with a 
new set of randomly selected human genes each time (genes and corresponding 3’-UTR 
sequences were downloaded from http://www.targetscan.org). These score distributions are 
then used to calculate an empirical p-value of the targeting score for each miRNA in the target 
gene set. Genes were selected at random from a pool with similar overall connectivity to the 
genes in the target gene set, and to account for differences in the average 3’ UTR length 
between the genes of interest and the randomly selected genes in each simulation, the targeting 
score was normalized by 3’ UTR length.  
miRhub algorithm: 
Inputs:  
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1. A list of predicted target sites for miRNA families in the multiple-sequence aligned 3’-UTRs 
of all genes for a set of species. This input can be acquired from TargetScan 
(http://www.targetscan.org).  
2. A list containing the conservation (number of species) of each of the miRNA families 
included in the above TargetScan predictions. This list can be parsed out of the files 
available from the TargetScan website. 
3. A list of high confidence protein-protein interactions. This list was derived from the STRING 
9.0 database (http://string-db.org/) using only those interactions having an interaction score 
greater than 700 (high-confidence). All protein identifiers were mapped to their 
corresponding gene symbol. The gene symbol must match those used in the TargetScan 
predictions. 
4. A list of miRNA families: This list contains the miRNAs the user wishes to include in the 
enrichment analysis. All miRNAs must be in the TargetScan miRNA family name format, and 
must match the family names in the Target Scan output file. 
5. Gene list: A list of genes to use as central nodes in a gene network. Typically this list 
includes a set of genes relevant to the study of a particular disease or pathway. All gene 
names must match the gene symbol used in the TargetScan 3’-UTR sequence files. 
Parameters:  
1. C: Conservation level. Requested minimum level of conservation of each miRNA and target 
site required for a miRNA - gene interaction to be scored in the simulation. 
2. N: Number of iterations. Requested number of random gene networks of similar design that 
are used to generate score distributions. 
3. α: Hub weighting. This parameter is used to weight the contribution of the number of high-
confidence protein-protein interactions to the target scoring function. 
A gene network is compiled using the input gene list and the connections from the 
protein-protein interaction database. The input gene network contains (1) all genes in the input 
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gene list that have a 3’-UTR listed in the target prediction files, (2) a weighted set of scores for 
each target site within each gene, and (3) the number of high confidence protein - protein 
interactions listed for that gene in the STRING 9.0 database. Each random gene network is 
generated by selecting a set of random genes having connectivity similar to each of those in the 
input gene list. A gene is said to have similar connectivity if the gene has a similar number of 
high confidence interactions in the STRING 9.0 database. To compute groups of genes with 
similar connectivity, we group each gene in the STRING 9.0 database by the number of high 
confidence protein-protein interactions that gene has. If any group contains fewer than 20 
genes, the group is expanded to include neighboring groups (with both higher and lower number 
of interactions) until the new super-group contains at least 20 genes. Finally a score is 
computed that represents how strongly each miRNA family in the input list targets each gene 
network (input gene network and N random gene networks), and an empirical p-value is 
computed. The p-value is calculated as p=(Nr+1)/(N+1), where Nr is the number of random 
gene networks in which the targeting score for a particular miRNA was greater or equal to the 
score of that miRNA in the input gene network. The miRNA targeting score is calculated using 
the following procedure: 
For a gene network G(L,D,U): where L is the list of genes in the network, D is the 
number of high confidence protein-protein interactions that each gene has, and U is the ratio of 
the average 3’-UTR length in the input gene network over the average 3’-UTR length in the 
current gene network (note: this value is one when scoring the input gene network). 
 
miRhub pseudocode: 
For each miRi in miRlist having a conservation of at least C: 
For each genej in L: 
For each target site k of miRi in genej: 
 𝑆𝑐𝑜𝑟𝑒𝐴!"# = 1.5      𝑖𝑓 8𝑚𝑒𝑟 − 1𝑎1.25     𝑖𝑓 7𝑚𝑒𝑟 −𝑚81    𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒  
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  𝑆𝑐𝑜𝑟𝑒𝐵!"# = 𝑆𝑐𝑜𝑟𝑒𝐴!"# 𝑖𝑓 𝑠𝑖𝑡𝑒 𝑖𝑠 𝑐𝑜𝑛𝑠𝑒𝑟𝑒𝑑 𝑖𝑛 ≥ 𝑪 species0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒  
For each miRi in miRlist having a conservation of at least C: 𝑆𝑐𝑜𝑟𝑒! = 0 
For each genej in L: 𝑆𝑐𝑜𝑟𝑒𝐶!" = 𝑆𝑐𝑜𝑟𝑒𝐵!"! 
For each additional target site k of miRi in genej: 𝑆𝑐𝑜𝑟𝑒𝐶!" += 0.5 ∗ 𝑆𝑐𝑜𝑟𝑒𝐵!"# 𝑖𝑓 (𝑃𝑜𝑠! − 𝑃𝑜𝑠!!!) ≤ 81.5 ∗ 𝑆𝑐𝑜𝑟𝑒𝐵!"# 𝑖𝑓 8 < (𝑃𝑜𝑠! − 𝑃𝑜𝑠!!!) < 60𝑆𝑐𝑜𝑟𝑒𝐵!"# 𝑖𝑓 (𝑃𝑜𝑠! − 𝑃𝑜𝑠!!!) ≥ 60   
Where Posk is the position of target site k within the 3’-UTR of genej. 𝑆𝑐𝑜𝑟𝑒! += 𝑼 ∗ 𝑆𝑐𝑜𝑟𝑒𝐶!" 1 + 𝜶 ∗ 𝑙𝑜𝑔10 𝑫!   𝑆𝑐𝑜𝑟𝑒! = 𝑆𝑐𝑜𝑟𝑒! 𝑠𝑖𝑧𝑒(𝑳) 
 
4.3.2 Candidate 5’-shifted isomiR regulatory hubs in type 2 diabetes 
Genome-wide association studies for type 2 diabetes (T2D) have primarily (though not 
exclusively) implicated genes with critical function in the pancreatic beta cell[101,102]. 
Therefore, we sought to determine if any of the highly expressed human beta cell miRNAs, 
including 5’-shifted isomiRs (identified in Chapter 2), serve as regulatory hubs in T2D. We first 
assembled a list of genes (n=92) implicated in T2D and related conditions including maturing 
onset diabetes of the young (MODY) (Methods). We then applied the miRhub algorithm to 
determine for each miRNA whether the predicted regulatory impact on T2D genes is 
significantly (uncorrected P < 0.05) greater than expected by chance (such miRNAs are termed 
“candidate regulatory hubs”). We identified 10 candidate miRNA regulatory hubs (Figure 4.1A. 
The top two were the 5’-reference miRNAs miR-29 and let-7, both of which have been 
implicated in beta cell function and glucose homeostasis [87,91,92]. Though miR-29 has been 
shown to regulate glucose-stimulated insulin secretion, its target genes in the beta cell are 
largely unknown. To validate the in silico approach, we selected several predicted targets 
(Camk1d, Glis3, and Jazf1), and one previously validated target (Slc16a1 [87]), of miR-29 from 
among the T2D gene list for evaluation in MIN6 cells. Specifically, we transiently transfected 
MIN6 cells with a miR-29 mimic or inhibitor (antagomiR) and measured the mRNA levels of 
each of the four genes by real-time quantitative PCR (RT-qPCR). Three of the four genes were 
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significantly (p < 0.05) down-regulated by the over-expression of miR-29 and three genes were 
significantly (p < 0.05) up-regulated by the antagomiR-mediated inhibition of miR-29 (Figure 
4.1B). These findings are consistent with previous reports that miR-29 is involved in the 
regulation of beta cell function [87,103], and they serve as a validation of the in silico regulatory 
hub analysis. 
Strikingly, three of the 10 candidate miRNA regulatory hubs in the T2D gene network 
were 5’-shifted isomiRs: miR-375+1, miR-375-1, and miR-183-5p+1 (Figure 4.1A). Moreover, all 
three of these were more significantly associated with T2D genes than their 5’-reference 
counterparts. This is particularly intriguing, given the already well-established role of 5’-
reference miR-375 in beta cell formation and function.  
 
4.3.3 5’-shifted isomiRs of the beta cell-enriched miRNA, miR-375 
As depicted in Figure 2.3C, miR-375 and its 5’-isomiRs have overlapping, but distinct 
predicted target gene profiles. To further evaluate the putative differential targeting of the miR-
375 5’-isomiRs, we selected the following three genes: Mtpn, which regulates insulin secretion, 
is a known target of the 5’-reference miR-375[48], but is not predicted to be targeted by the 5’-
shifted isoforms; Atp6v0c, which mediates glucose-sensitive intracellular vesicular transport and 
is predicted to be preferentially targeted by the 5’-shifted isoform miR-375+1; and Cdc42, which 
is essential for the second phase of insulin secretion and is predicted to be preferentially 
targeted by the 5’-shifted isoform miR-375-1. We transfected MIN6 cells with (1) transfection 
reagent only (mock), (2) 10nM of miR-375 mimic, or (3) 10nM of a mimic for one of the 5’-shifted 
isomiRs of miR-375, and measured the mRNA levels of each of the three genes by RT-qPCR. 
Mtpn was repressed only by the 5’-reference miRNA (Figure 4.2). Atp6v0c and Cdc42 were also 
modestly repressed by the 5’-reference miRNA, though slightly more so by miR-375+1 and miR-
375-1, respectively (Figure 4.2). In each case, the strongest repression was conferred by the 5’-
isomiR with the strongest predicted target site. 
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Figure 4.1: Candidate miRNA regulatory hubs in a type 2 diabetes gene network. (A) Each 
data point represents a 5′-reference miRNA or a 5′-shifted isomiR from primary human beta 
cells, and the y-axis shows the negative Log2 of the p-value of the predicted miRNA targeting 
score among genes in a type 2 diabetes (T2D) network. The dashed red line denotes the 
significance threshold (empirical P = 0.05). (B) Effects of miR-29 mimic and inhibitor in MIN6 
cells on the mRNA levels of four T2D genes are shown. The x-axis lists the gene symbols for 
each of four predicted miR-29 target genes and the y-axis depicts the relative quantitative value 
(RQV; expression determined by RT-qPCR and normalized to Rps9) in response to the miR-29 
mimic (blue) or the miR-29 inhibitor (red) relative to mock transfection. The data shown 
represent at least two independent experiments, each conducted in triplicate. P-values were 
calculated based on Student’s t-tests. *, P<0.05; **, P<0.01. 
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Figure 4.2: Evaluation of miR-375 and its 5′-shifted isomiRs in MIN6 cells. Effects of 
mimics for 5′-reference miR-375, 5′-shifted miR-375+1, and 5′shifted miR-375-1 in MIN6 cells on 
the mRNA levels of three genes are shown. Mtpn is a known target of 5′-reference miR-375 but 
not predicted as a target for either of the 5′-shifted miR-375 isomiRs; Atp6v0c is predicted to be 
preferentially targeted by miR-375+1; and Cdc42 is predicted to be preferentially targeted by 
miR-375-1. The x-axis lists the gene symbols for each of three genes tested. The y-axis depicts 
the relative quantitative value (RQV; expression determined by RT-qPCR and normalized 
to Rps9) in response to the miR-375 mimic (gray), miR-375+1 mimic (orange), or miR-375-1 
mimic (green) relative to mock transfection. The data shown represent at least two independent 
experiments, each conducted in triplicate. P-values were calculated based on Student’s t-tests. 
*, P<0.05; **, P<0.01, ***, P<0.001. 
 
4.4 Discussion 
In this chapter we discussed an in-house miRNA target site enrichment algorithm 
(miRhub) that we developed to identify miRNAs and isomiRs that act as candidate master 
regulators of genes associated with T2D. Using this algorithm, we identified 10 beta cell 
miRNAs, including three 5’-shifted isomiRs, as candidate regulatory hubs in type 2 diabetes. We 
evaluated several predicted gene targets of our top candidate regulatory hub, miR-29, and 
demonstrated the potential of the 5’-shifted isomiRs miR-375+1 and miR-375-1 to differentially 
regulate gene expression in MIN6 cells.  
While the unambiguous validation of the targeting activity of 5’-shifted isomiRs is 
important, it is hindered by inherent limitations of the currently available technologies. For 
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example, the gold standard experiment would be to specifically knock-down the 5’-shifted 
isomiR of interest. However, current strategies for knock-down (e.g. locked nucleic acids), and 
for testing the efficacy of the knock-down (e.q. TaqMan RT-qPCR), do not adequately 
distinguish between the 5’-reference and 5’-shifted isoforms. New approaches for studying 
miRNA function must be developed in order to tackle the technical challenges posed by 5’-
shifted isomiRs, which are often identical in sequence to the 5’-reference form except for the 
addition/loss of a single nucleotide at the 5’-end. Though outside the scope of this study, further 
analyses are necessary to firmly establish the functional relevance of the 5’-shifted isomiRs. 
Nonetheless, to our knowledge, this is the first report of highly expressed 5’-shifted isomiRs in 
beta cells, several of which are candidate regulatory hubs in T2D.  
The findings in this study promote the notion that 5’-shifted isomiRs are prevalent and 
potentially impact disease, thus widening the panoramic view of the functional miRNA-ome. In 
addition, we have identified for the first time three 5’-shifted isomiRs as significant candidate 
regulatory hubs in a disease network. The novel strategy employed in this study can be utilized 
for additional disease models to uncover potential roles for 5’-shifted isomiRs in the regulatory 
networks of complex diseases. 
 
4.5 Materials and methods 
Candidate miRNA regulatory hub identification in the T2D gene network 
T2D gene list: We identified the nearest genes to each genetic variant significantly 
associated with T2D (p-values < 10-7) from (1) the T2D genome-wide association studies 
(GWAS) listed in the NHGRI catalog (http://www.genome.gov/gwastudies) and (2) a GWAS 
reported by Morris et al. that was not included in the NHGRI catalog [104]. Additionally, we 
included twenty-three genes linked to maturity onset diabetes of the young (MODY), neonatal 
diabetes (NDM), and chronic hyperinsulinemia (CHI). The total number of genes was 92. 
Validation of miRNA-mediated gene regulation 
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MIN6 cells were transiently transfected with (1) 10nM mmu-miR-29 mimic (Dharmacon); 
(2) 200nM mmu-miR-29 hairpin-inhibitor (Dharmacon); (3) 10nM mmu-miR-375 mimic 
(Dharmacon); (4) 10nM custom mmu-miR-375+1 mimic (Dharmacon: 5’-
UUGUUCGUUCGGCUCGCGUGA-3’) or (5) 10nM custom mmu-miR-375-1 mimic (Dharmacon: 
5’UUUUGUUCGUUCGGCUCGCGUGA-3’). After 48 hours, RNA was extracted from cells using 
the Norgen Total RNA Purification Kit, and miRNA and mRNA levels were measured by real-
time quantitative PCR (RT-qPCR) using TaqMan microRNA and gene assays (Applied 
Biosystems). 
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CHAPTER 5: AN INTEGRATIVE TRANSCRIPTOMICS APPROACH IDENTIFIES MIR-503 AS 
A CANDIDATE MASTER REGULATOR OF THE ESTROGEN RESPONSE 
 
5.1 Overview 
Estrogen receptor α (ERα) is an important biomarker of breast cancer severity and a 
common therapeutic target. In response to estrogen, ERα stimulates a transcriptional program 
including both coding and non-coding RNAs. However, although ERα is known to cyclically bind 
to estrogen response elements and initiate bursts of transcriptional activity, most studies assess 
only one or two time points in response to estrogen and thus fail to capture the fine-scale gene 
expression dynamics. With a map of this dynamic response, we can define the varying temporal 
patterns of expression regulated by ERα, which would greatly enhance the study of the 
regulatory network that underlies the estrogen response. In this chapter, I use the tools and 
techniques I developed and described in Chapter 2-4 to create and analyze the dynamic 
response of mRNAs and miRNAs to estrogen stimulation in breast cancer.  
  To determine how ERα signaling regulates gene expression dynamics, we performed 
temporal profiling of both messenger RNAs (mRNAs) and microRNAs (miRNAs) in MCF7 cells 
(an ER+ model cell line for breast cancer). Cells were cultured in estrogen free media, then 
exposed to estrogen and paired mRNA and miRNA sequencing libraries were generated at ten 
time points throughout the first 24 hours of the response to estrogen. We identified three 
primary expression trends—transient, induced, and repressed—that were each enriched for 
genes with distinct cellular functions. Integrative analysis of mRNA and miRNA temporal 
expression profiles identified miR-503 as the strongest candidate master regulator of the 
estrogen response, in part through suppression of ZNF217—an oncogene that is frequently 
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amplified in cancer. We confirmed experimentally that miR-503 directly targets ZNF217 and that 
over-expression of miR-503 suppresses breast cancer cell proliferation. Overall, these data 
indicate that miR-503 acts as a potent estrogen-induced candidate tumor suppressor miRNA 
that opposes cellular proliferation and has promise as a novel therapeutic for breast cancer. 
More generally, our work provides a systems-level framework for identifying functional 
interactions that shape the temporal dynamics of gene expression. 
 
5.2 Introduction 
Breast cancer remains a prevalent cause of cancer-related death in women world-wide, 
and is categorized into at least five molecular subtypes that differ from each other in terms of 
biomarkers, etiology, and treatment modalities [25]. By far the most predominant forms of breast 
cancer are those that stain positive for the estrogen receptor (ER+). The ER, in particular ERα 
(encoded by the ESR1 gene), has been widely studied in breast cancer [26-28]. ERα binds to 
estrogen (usually estradiol or E2), dimerizes, and translocates to the nucleus where it recruits 
co-activators or co-repressors to estrogen response elements (EREs) [28]. ERα is thought to be 
the primary receptor involved in the estrogen response of both normal and breast cancer cells 
[105]. 
In response to estrogen, ERα stimulates a transcriptional program involving both coding 
[26,29,106-109] and non-coding [41,110] RNAs. While numerous studies have investigated the 
coding transcriptional program, only a few studies have investigated the role played by 
microRNAs (miRNAs). Nevertheless, at least five miRNAs (miR-22, miR-222, miR-221, miR-18a 
and miR-206) have been identified that are both repressors of the ESR1 mRNA and regulated 
by ERα [28]. Post-transcriptional regulation of ESR1 is of significant interest in breast cancer 
because it is one proposed mechanism for loss of ERα expression in ER(-) tumors [32]. In 
another study, miR-375 was identified as an epigenetically deregulated miRNA that amplifies 
estrogen signaling in ER+ breast cancers [111]. Importantly, in that study, the inclusion of miR-
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375 in a newer microarray probe set allowed the authors to identify a role for miR-375 in ER+ 
tumors. This highlights the importance of investigating miRNA expression via high-throughput 
sequencing, which is more sensitive and less biased than microarrays, and could potentially 
expand the set of miRNAs with potential relevance to the estrogen response.  
Although high-throughput sequencing has increased in popularity and decreased in cost 
over the last decade, it has not been extensively applied toward the study of the gene 
expression response to estrogen. While microarray studies have identified a working set of 
estrogen responsive genes and miRNAs, these studies are limited by several factors. Firstly, 
microarrays can only identify targets for which probes exist and are subject to cross-
hybridization errors [112]. Secondly, to date, most studies have assessed only one or two time 
points in response to estrogen, which fails to capture the full dynamic responses of ERα targets. 
ERα is known to cyclically bind to EREs and initiate bursts of transcriptional activity [39,113], 
and individual estrogen responsive mRNAs have been shown to exhibit diverse dynamical 
patterns of expression following estrogen stimulation [109]. Finally, to date no study has 
quantified both coding and non-coding RNAs in the same total RNA in response to estrogen. 
The estrogen response is highly dependent on the conditions of the study [114], and small 
changes in experimental design make it difficult to combine multiple studies together. In 
summary, the body of work on the estrogen response has demonstrated that ERα signaling 
enacts a dynamic and multilayered gene expression program, but we have very little 
understanding of how estrogen-stimulated regulatory networks change over time. The study of 
regulatory networks is greatly enhanced by the inclusion of temporal data, as it expands static 
interaction diagrams into dynamic models that can uncover complex behaviors, such as the 
generation of expression thresholds [42], or the existence of stable points that allow the cell to 
maintain expression in the absence of continued stimulation. 
In this study, we investigate the global response to estrogen stimulation by analyzing 
paired messenger (mRNA) and miRNA measurements over time in MCF7 breast cancer cells. 
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We identify three major patterns of gene expression following estrogen stimulation and uncover 
miR-503 as an important estrogen-induced master regulator of the overall estrogen response. 
Based on these computational predictions, we confirm experimentally that miR-503 suppresses 
proliferation in breast cancer cells, and we identify a new target of miR-503, the oncogene 
ZNF217. These results provide a quantitative understanding of the temporal response of 
mRNAs and miRNAs to estrogen stimulation, and suggest that miR-503 is a candidate 
therapeutic target for treatment of breast cancer. 
 
5.3 Results 
To study the dynamics of gene expression in response to estrogen stimulation, we 
performed a parallel set of time-series measurements for mRNAs and microRNAs (Figure 5.1). 
We cultured MCF7 cells (a luminal A-type / ER+ cancer cell line) in stripped (estrogen-starved) 
media for 72 hours to synchronize cells in an estrogen-free state. At time zero, we 
supplemented the media with 10nM β estradiol (E2) and maintained the cells in this media for 1-
24 hours. At each of ten time points (hourly from 0-6 hours after E2, and 8, 12 and 24 hours 
after E2), with three independent biological replicates for each, cells were harvested and used 
to prepare both small RNA and PolyA+ RNA libraries from the same total RNA sample for high-
throughput sequencing. The PolyA+ RNA libraries had an average read depth of ~65 million 
reads (>90% of reads aligned uniquely), and the small RNA libraries had an average read depth 
of ~32 million reads (~90% of reads aligned). The expression levels of selected genes and 
miRNAs were confirmed by RT-qPCR (Supplementary Figure 5.1). 
	 58	
 
Figure 5.1: Experimental design. MCF-7 cells were cultured in stripped media for 72hrs, then 
10nM E2 was added to the media. RNA was harvested at 0,1,2,3,4,5,6,8,12 and 24hrs post E2, 
and paired small RNA and RNA-seq libraries were generated. Each dataset was subject to 
differential expression analysis, and interactions were predicted between miRNAs and target 
mRNAs. 
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Figure 5.2: Gene expression response to estrogen stimulation. (A) The expression profile 
of 1546 mRNAs that have a significant (adjusted p-value <0.05) ≥2-fold change at one or more 
time points in response to estrogen stimulation, and a mean normalized expression of at least 
500 across the time series. Genes clustered into three classes (Transient, Repressed, and 
Induced). (B-D) Expression of FOXC1, ZNF217 and TFF1, examples of transient, repressed 
and induced gene classes. (E-F) Gene Ontology analysis of genes in the transient (E), 
repressed (F) and induced (G) gene classes. 
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5.3.1 Dynamics of estrogen-regulated mRNAs  
Differential gene expression was calculated for each time point relative to time zero. 
Those genes with a mean normalized expression count across the time-series of at least 500, 
and a significant (adjusted p-value<0.05) ≥2-fold change relative to time zero at any time during 
the 24 hours, were considered to be estrogen-responsive. In total, 1546 genes met these 
criteria. Using this condensed data set, we then examined the dynamics of gene expression. By 
clustering the time series, we were able to stratify the 1546 genes into three temporal patterns 
of gene expression (Figure 5.2A). The first class includes 468 genes that show transient 
induction in response to estrogen. For example, the gene encoding the forkhead transcription 
factor, FOXC1, which is an important biomarker of basal-like breast cancer[115], is lowly 
expressed at time zero, exhibits a brief but significant increase in expression, and then 
stabilizes at a new equilibrium state around 5 hours after estrogen stimulation (Figure 5.2B). 
Both peak times and peak widths are variable within this class. Approximately 11% of the genes 
in this list have previously been identified (by meta analysis of microarray studies) to be up 
regulated at ~4hrs after estrogen stimulation [34]. The second class includes 608 genes that 
exhibit overall decreases in expression over time. These “repressed” genes include ESR1 (gene 
encoding ERα), ERBB2, GATA3, and ZNF217 (Figure 5.2C)—all critical genes to the etiology of 
breast cancer [23,27,116,117]. ZNF217, a notable member of this class of genes, is a Krüppel-
like finger (KLF) protein that acts as a transcriptional regulator that amplifies the estrogen 
response in breast cancer [117] and has been identified as a biomarker of poor survival in 
patients with Luminal A (ER+) breast tumors [118]. Approximately 40% of the genes in the 
repressed class were previously identified as down regulated at 24hrs after estrogen stimulation 
[34]. Finally, 470 genes are induced by estrogen stimulation. Included in this class are TFF1 
(Figure 5.2D; Supplementary Figure 5.1) and CTSD (Supplementary Figure 5.1), for which there 
exists a detailed time course of ChIP data showing cyclic occupancy of ERα on their 
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promoters[39,113]. Approximately 56% of these genes have been previously identified as up 
regulated at 24hrs post-estrogen stimulation, including known breast cancer genes BRCA1, 
BRCA2, and E2F1[119]. Gene ontology (GO) analysis indicates that each of these three classes 
of genes is enriched for distinct functional categories (Figure 5.2E-G). The transient group of 
genes shows enrichment for GO terms dealing with cell migration and motility (Figure 5.2E), the 
repressed group for terms involving mammary development and differentiation (Figure 5.2F), 
and the induced category for functions relevant to cell cycle progression (Figure 5.2G). Taken 
together, this analysis reveals a complex and multilayered gene expression program with 
different temporal patterns of expression associated with distinct cellular functions. 
 
Figure 5.3: Most genes reach ≥ 2-fold change at few and disparate time points. (A) The 
number of time points during the 24hr collection for which each of the 1546 estrogen responsive 
genes reaches a ≥ 2-fold change from time zero. (B) The number of time points during the 24hr 
collection for which genes within the three classes reach a ≥ 2-fold change from time zero. (C) 
The expression profile of NCOR2, a representative gene from the transient class reaches ≥2-
fold change from time zero at three of the time points. (D) The expression profile of GATA3, a 
representative gene from the repressed class reaches ≥2-fold change from time zero at one 
time point. (E) The expression profile of BRIP1, a representative gene from the induced class 
reaches ≥2-fold change from time zero at three of the time points. All plots show the mean of 
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three biological replicates as a blue line with box and whisker plots showing the variation in 
normalized expression among the replicates, and regions ≥2-fold different than time zero are 
shaded in gray. 
It is important to note that our high-resolution temporal analysis identified many 
estrogen-responsive genes that would have been missed had we taken a more conservative 
approach and examined only one or few time points. We find that 59% (n=905) of the estrogen-
responsive genes exhibit ≥2-fold change at three or fewer time points; furthermore, 34% 
(n=528) of the estrogen-responsive genes exhibit ≥2-fold change at only a single time point 
(Figure 5.3A). This observation that a large proportion of estrogen-responsive genes are 
significantly altered at only a few time points, and not necessarily at the same time points, is 
evident in all three classes of response patterns (Figure 5.3B). These data highlight the added 
value of a high-resolution temporal analysis. For example, consider nuclear co-repressor 2 
(NCOR2), which is a member of the same nuclear receptor super-family as ERα, and has been 
associated with early tumor recurrence in breast cancer [120]. NCOR2 is only ≥2-fold up 
regulated at three out of the 10 time points analyzed (2-4 hours post estrogen stimulation) 
(Figure 5.3C, adjusted p-value = 4e-17 at 2hrs, 1e-11 at 3hrs, 2e-9 at 4hrs post E2). A study 
designed to assess estrogen-responsive genes at 12 or 24 hours post-stimulation would detect 
virtually no difference in gene expression levels of NCOR2. Additionally, within the repressed 
class, a group of genes drop significantly in expression in the first two hours after estrogen 
stimulation, but then recover at an expression level roughly 60% of the expression at time zero 
(Supplemental Figure 5.2A). Both GATA3 (Figure 5.3D) and ESR1 are members of this class, 
and these encode transcription factors that not only regulate each other [121], but also co-
regulate many target genes [37]. GATA3 is ≥2-fold down regulated only at two hours post 
estrogen. Nearly half of the genes in the induced class reach a ≥2-fold up-regulation (adjusted 
p-value < 0.05) at only a single time point (Figure 5.3B). Finally, BRIP1 (BRCA1 interacting 
protein C-terminal helicase 1; Figure 5.3E) is an example of a gene in the induced class that is 
detected as differentially expressed at only three time points (all after eight hours post estrogen 
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stimulation). These observations demonstrate the dynamic nature of gene expression in 
response to estrogen and the importance of collecting and analyzing high-resolution time series 
data to fully capture these dynamics. 
We also identified two groups of genes displaying opposite temporal responses to 
estrogen. The first group of 170 genes displays a temporal response to estrogen similar to that 
of GATA3 (Supplementary Figure 5.2A). The importance of both GATA3 and ERα in regulating 
the estrogen response has been established [37]; therefore, these 170 genes may include other 
members of this regulatory network, either additional co-regulators of ERα or genes regulated 
by these transcription factors. The second group includes 118 genes that exhibit a temporal 
response to estrogen that is opposite of the GATA3-like genes (Supplementary Figure 5.2B). 
The opposite temporal responses of these groups suggest a possible inhibitory relationship 
between members of the two groups. To further explore this inverse relationship, we sought to 
identify potential negative regulators of ESR1 or GATA3 within the anti-GATA3 group. To that 
end we assessed the correlation between both ESR1 and GATA3 and genes within the anti-
GATA3 group in The Cancer Genome Atlas (TCGA) breast cancer dataset (https://tcga-
data.nci.nih.gov/tcga/). The transcription factor FOXC1 (Figure 5.1B), an important biomarker of 
basal-like breast cancer[115], is a member of the anti-GATA3 group and is anti correlated with 
GATA3 expression in TCGA data (Supplementary Figure 5.2C; Pearson’s r=-0.602). This 
analysis confirms previous findings that FOXC1 and GATA3 are involved in a switch 
(Supplementary Figure 5.2D) between basal-like and luminal-like expression programs in breast 
cancer [122], and indicates that the high-resolution time-series data may identify novel factors 
that underlie this switch.  
 
5.3.2 Dynamics of estrogen-regulated miRNAs  
To understand how the temporal gene expression patterns are regulated, we next 
sought to characterize the dynamics of miRNA expression in response to estrogen. Small RNA-
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seq data were processed as previously described [20] to identify robustly expressed miRNAs 
and their isoforms (isomiRs). Resulting miRNA counts were normalized using a reads-per-
million-mapped (RPMM) transformation. We detected 308 miRNAs with a mean expression of at 
least 50 RPMM across all samples. Consistent with previous studies of MCF7 cells [41], among 
the most highly expressed miRNAs in the dataset are miR-21-5p, miR-200c-3p, the let-7 family, 
and miR-93-5p.  
To identify estrogen-responsive miRNAs, the expression of each miRNA was normalized 
to the mean of the three replicates at time zero. Of the 308 expressed miRNAs, 10 exhibited a 
fold change of at least 1.5 (uncorrected p-value <=0.05) at some time point during the 24 hours 
(Figure 5.4A), and 5 miRNAs had a fold change greater than 2 (uncorrected p-value <=0.05; 
miR-503, miR-424-3p, miR-1247-5p, miR-196a-1-5p and miR-196a-2-5p). The miRNA with the 
highest fold change following estrogen stimulation is miR-503 (Figure 5.4B), with a ~6-fold 
increase by 24 hours post estrogen stimulation. Interestingly, the second-most strongly 
increased miRNA is miR-424-3p (Figure 5.4C), which is encoded on the same primary transcript 
as miR-503. Although literature corresponding to miR-424 usually refers to miR-424-5p, in our 
data miR-424-3p is more consistently expressed across replicates, has a higher mean 
expression across the time series, and has a greater fold increase than miR-424-5p. miR-1247-
5p exhibits a 3-fold increase in response to estrogen stimulation, and both paralogs of miR-
196a-5p (Figure 5.4D) are ~2-fold increased by 4 hours after estrogen stimulation.  
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Figure 5.4: miRNA expression response to estrogen stimulation. (A) The expression profile 
of 10 miRNAs that have a ≥1.5 mean fold change at least one time point in response to 
estrogen stimulation, and a mean normalized expression of at least 50 RPMM. The expression 
profiles of miRNAs were clustered using a hierarchical clustering method. (B-D) Plots show the 
expression of the most estrogen responsive miRNA, miR-503 (B), miR-424-3p (C), and miR-
196a-1-5p (D). All plots (B-D) show the mean of three biological replicates as a blue line with 
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box and whisker plots showing the variation in normalized expression among the replicates. (E) 
This plot shows the –Log10 (uncorrected p-value) of enrichment for each miRNA family among 
the genes that are characteristic of the change in expression between each time interval. 
miRNA families on the x-axis are sorted by decreasing significance (sum across all time 
intervals). 
 
5.3.3 Computational prediction of miRNA-mRNA regulatory interactions 
We next explored the potential regulatory interactions between miRNAs and mRNAs in 
the temporal response to estrogen using our previously published miRNA target site enrichment 
algorithm, miRhub [20]. miRhub identifies candidate master miRNA regulators by identifying 
those miRNAs that are predicted to target and regulate a gene set of interest significantly more 
than expected by chance. We sought to not only identify potential miRNA-mRNA regulatory 
interactions throughout the entire time course but to determine the specific time points at which 
these interactions were most significant. To do this, we used the Characteristic Directions 
method [123] to identify the sets of genes whose combined expression best distinguish the 
expression profiles between consecutive time points. We then assessed all expressed miRNA 
families to determine whether any are candidate “master regulators” of these sets of 
“characteristic genes”. Using this approach, miR-503 consistently emerged as the most 
significant candidate master miRNA regulator (Figure 5.4E). It was particularly prominent at time 
points 1hr, 2hr, 3hr, and 4hr post-treatment. Thus, miR-503 is both the most estrogen-
responsive miRNA as well as the miRNA with the largest predicted impact on the dynamic gene 
expression response to estrogen.  
Following our identification of miR-503 as a potential master regulator of the estrogen 
response, we next sought to identify potential targets of miR-503. Our miRNA target site 
enrichment analysis revealed 28 genes that are predicted targets of miR-503 (Figure 5.5A). One 
of the predicted targets, CCND1 (Figure 5.5B), has already been validated as a target of miR-
503 and the repression of CCND1 by miR-503 has been reported to inhibit proliferation in breast 
cancer cell lines [124]. Another predicted target, ZNF217 (Figure 5.5C), 
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as a miR-503 target but was recently identified as both a biomarker and an oncogene in breast 
cancer [117]. As a final example, RET (Figure 5.5D) is a proto-oncogene that is reported to be 
transcriptionally up regulated in numerous human cancers [125]. Other genes within the list of 
potential miR-503 targets provide potentially interesting insights into the estrogen response 
regulatory network in breast cancer and warrant further study (Figure 5.5A).  
Among these predicted miR-503 targets, ZNF217 is of particular interest because of its 
known mechanistic role in the estrogen response. ZNF217 binds to many of the same 
promoters as the three transcription factors that coordinate the overall response to estrogen 
stimulation (ERα, GATA3 and FOXA1)[37,118]. Additionally, the c-terminus of ZNF217 
physically binds to the hinge domain of ERα and enhances recruitment of ERα to EREs [126]. 
We carried out ChIP-X enrichment analysis (ChEA)[127] and found that ZNF217 binding sites 
are over-represented in estrogen responsive genes in our data set (Supplementary Figure 5.3). 
During the first four hours post-estrogen-treatment, the behavior of ZNF217 bears strong 
resemblance to that of GATA3. However, unlike GATA3, ZNF217 fails to recover from >2-fold 
repression and remains 2-fold down regulated for the rest of the time course. In fact, the first 
time point that ZNF217’s fold difference in expression deviates from that of GATA3 is at four 
hours post estrogen stimulation. At that same time point (hour 4), miR-503 reaches a ~2-fold 
increase relative to time zero. Taking together these compelling observations with the etiological 
relevance of ZNF217 to breast cancer, we selected ZNF217 as a potential target of miR-503 for 
further investigation.  
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Figure 5.5: Potential miR-503 targets. (A) The expression profile of 28 miR-503 targets 
mRNAs that are characteristic of the difference in gene expression between consecutive time 
points. The expression profiles of miRNAs were clustered using a hierarchical clustering 
method. (B-D) Plots show the expression of miR-503 and its validated target CCND1 (B), 
predicted targets ZNF217 (C) and RET (D). All plots (B-D) show the mean of three biological 
replicates as a blue line with box and whisker plots showing the variation in log2 (fold change) 
between replicates. (E) miR-503 target site in the ZNF217 3’-UTR. A dual luciferase reporter 
was used to validate the response of ZNF217 to miR-503. The reporter was mutated by 
inserting two As (red) to disrupt the “seed”-region binding of miR-503. (F) Response of the 
ZNF217 reporter and mutant reporter with and without 10nM miR-503 mimic. Significance 
assessed using a student’s t-test.  
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5.3.4 miR-503 targets ZNF217 and suppresses cellular proliferation 
To validate the repression of ZNF217 by miR-503 we carried out 3’-UTR-reporter gene 
assays. Specifically, we co-transfected miR-503 in MCF7 cells with dual-luciferase expression 
vectors containing a Renilla luciferase reporter gene (internal control) and a Firefly luciferase 
reporter gene linked to either the wild-type ZNF217 3’-UTR or a mutated version of the ZNF217 
3’-UTR reporter with two adenosines inserted between the bases opposite of nucleotides 3 and 
4 in the predicted miR-503 target site (Figure 5.5E). This mutation abolishes the perfect match 
to the miR-503 “seed” region, and therefore is expected to compromise the efficacy of miR-503 
targeting. We found that miR-503 significantly (p=0.003) reduces the relative levels of the wild-
type ZNF217 3’-UTR reporter, whereas the mutation in the miR-503 target site rescues this 
effect completely (Figure 5F). Together these results indicate that miR-503 represses ZNF217 
in MCF7 cells via direct targeting of its 3’-UTR. Because ZNF217 is an oncogene, these findings 
strongly support miR-503 as a candidate tumor suppressor in breast cancer. 
The role of miR-503 in opposing proliferation has been very recently investigated in 
breast cancer [124,128], prostate cancer [129] and osteosarcoma [130]. One previous study in 
MCF7 cells demonstrated that overexpression of miR-503 was able to inhibit cell cycle 
progression through repression of CCND1 [124]. Based on our findings that miR-503 targets 
ZNF217, which promotes cell cycle progression [131], we hypothesized that the anti-proliferative 
effect of miR-503 resulted from a G1 arrest. To test this prediction, we transiently transfected 
MCF7 cells with miR-503 mimic (50nM). Cells were pulsed for 2 hours with EdU and fixed at 48 
and 72 hours after transfection. For each cell, the total EdU signal was plotted against the total 
DNA signal, and cell cycle stage was assigned. We found that MCF7 cells transfected with miR-
503 have a significantly reduced percentage of cells in S phase compared to mock transfection 
(Supplementary Figure 5.4A). This observation was observed at both 48 (p-value=0.01) and 72 
(p-value=0.03) hours after transfection with miR-503 (Supplementary Figure S4B). We validated 
the anti-proliferative effect of miR-503 by showing reduced amount of Ki67 protein 
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(Supplementary Figure 5.5). Together these data confirm that miR-503 inhibits proliferation in 
MCF7 cells, and that the oncogene ZNF217 is a novel target of miR-503. These findings 
motivate further mechanistic studies to determine whether the anti-proliferative role of miR-503 
is mediated through suppression of ZNF217. 
 
Figure 5.6: Summary. (A) Potential mechanism behind regulation of the three classes of 
estrogen responsive genes. (B) Summary mechanism showing the interaction of the estrogen 
responsive gene ZNF217 and the estrogen responsive miRNA miR-503. 
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An extensive body of literature exists detailing the importance of ERα in breast cancer, 
both as a biomarker of cancer severity and as a therapeutic target. Additional studies have 
highlighted the importance of various miRNAs in the etiology of breast cancer [41]. In this study, 
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a wealth of insight into the dynamics of the estrogen response. We observe similar temporal 
responses for genes that encode the transcription factors previously reported to be involved in 
positive feedback loops (ERα and GATA3 [121]) and opposite temporal responses for genes 
encoding transcription factors reported to inhibit each other (GATA3 and FOXC1 [122]). These 
temporal relationships allow us to make inferences about the estrogen stimulated regulatory 
network and enhance our understanding of the timing of the cascade of signaling stimulated by 
estrogen in breast cancer.  
This study is one of the few to investigate the temporal response of RNAs to stimuli in 
breast cancer, and is the first sequencing based study to investigate the matched temporal 
response of coding and non-coding RNAs to estrogen stimulation in breast cancer. A previous 
study used microarrays to investigate the response of genes and miRNAs to estrogen 
stimulation [40] but, interestingly, did not identify miR-503 as a significantly expressed miRNA. 
This discrepancy underscores the importance of using high throughput sequencing and fine-
grained time resolution to study the dynamics of gene expression. 
Estrogen stimulation induces a dynamic and varied response in 1546 mRNAs and 10 
miRNAs. The transient class of estrogen-stimulated mRNAs contains genes that peak for 
various lengths of time and at different time points following estrogen stimulation (Figure 5.6A). 
Such behavior may be due to an incoherent feed-forward loop architecture, wherein both a 
target gene and its repressor are activated leading to a pulse in gene expression[4]. The 
repressed category also exhibits significant variation, with a large group of genes behaving 
similarly to GATA3 (an initial drop in expression followed by a recovery at a new baseline 
expression level). Finally, the induced class of estrogen responsive mRNAs appears to either 
continually increase throughout the experiment as TFF1 (Figure 5.1D) or level off at some new 
higher expression level. Among the estrogen responsive miRNAs, miR-503 emerges as the 
most strongly responsive miRNA, though others that are >2-fold changed (miR-424-3p, miR-
1247-5p, miR-196a-1-5p and miR-196a-2-5p) warrant further investigation as well. 
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Interestingly, we also noted that a group of transient mRNAs has the exact opposite 
expression pattern to the GATA3-like group of repressed mRNAs (an initial increase followed by 
a reversion to a lower but still up-regulated expression level). A representative example of this 
group is FOXC1 (Figure 5.1B), an important regulator of Basal-like breast cancer and a 
repressor of GATA3 [122]. FOXC1 and GATA3 appear to be involved in a double negative-
feedback loop (mutual inhibition) that may influence the transition between luminal-like and 
basal-like tumor phenotypes (Supplemental Figure 2D). Tkocz et. al. showed that knockdown of 
GATA3 in luminal cells resulted in the expression of basal-like markers and cell morphology, 
while knockdown of FOXC1 in basal-like cells resulted in the expression of luminal markers and 
cell morphology [122]. It is interesting to observe this pulse in a master regulator of the basal-
like phenotype in response to estrogen. One explanation for this behavior is that the transition 
from estrogen-free media to estrogen rich-media may displace the ligand unbound estrogen 
receptor from its target sites and allow expression of genes that were repressed by the receptor 
in the absence of ligand. The introduction of estrogen would presumably then lead to the ligand-
bound estrogen receptor repressing those same genes.  
Among the targets (direct or indirect) of the ERα regulatory circuit are ZNF217 and miR-
503 (Figure 5.6B). ZNF217 is a transcriptional regulator that works together with ERα to amplify 
the estrogen response in breast cancer [117]. However, despite the association of ERα with 
proliferation, ZNF217 is repressed in response to estrogen stimulation in these data indicating 
that there may be a built-in mechanism to avoid the ZNF217-induced attenuation of the 
estrogen response. 
In this study, we identify three major patterns of gene expression following estrogen 
stimulation (1) transient, (2) induced, and (3) repressed. Among the genes repressed by 
estrogen stimulation is the oncogene ZNF217, which has been shown to enhance proliferation 
in ovarian [131] and breast cancer [132]. Additionally, we have shown that the estrogen-induced 
miRNA, miR-503, targets the 3’-UTR ZNF217 and that while miR-503 is induced in response to 
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estrogen, the oncogene ZNF217 is reduced. Together these observations point to the 
complexity of the estrogen-signaling network, and further highlight the beneficial aspects of the 
estrogen response. Several studies have recently shown that miR-503 may be a potent tumor 
suppressive miRNA. One such study showed that miR-503 targets CCND1 and reduces 
proliferation in both MCF7 and MDA-MB-231 cells (an ER (-) Claudin-low model) [124]. Others 
have shown that miR-503 reduces proliferation and metastasis in prostate cancer [129], in 
osteosarcoma [130], and in hepatocellular carcinoma[133]. Furthermore, loss of miR-503 has 
been reported in several human cancers, and is associated with poor prognosis in cervical 
cancer [134]. The induction of miR-503 in response to estrogen stimulation has anti-proliferative 
effects, likely through its repression of both CCND1 and ZNF217. Combined with the 
information that miR-503 is down regulated in human cancers, these results indicate that miR-
503 presents a new candidate therapeutic option for the treatment of breast cancer. 
 
5.5 Materials and methods 
Cell culture and estrogen treatment 
The Perou Lab at UNC Chapel Hill generously provided the MCF7 cells used in these 
experiments. Cells were cultured in Dulbecco’s modified eagle’s medium with nutrient mixture F-
12 Ham, 15mM HEPES and sodium bicarbonate and without L-glutamine and phenol-red 
(Sigma; St. Louis, MO; #D6434) supplemented with 10% charcoal stripped serum (Sigma; St. 
Louis, MO; #F6765) and 5% GlutaMax (Gibco; #35050-061). For each biological replicate, a 
single plate of cells was split into 10 separate cell culture plates (one for each time point). Cells 
were maintained in the stripped serum media for 72 hours, then the time zero batch of cells was 
scraped from the plate, pelleted and flash frozen in ethanol dry ice slurry. For the remaining 
cells (other time points), media supplemented with 10nM β-estradiol (Sigma; St. Louis, MO; 
#E2758) was added at time zero, and cells were collected at 1, 2, 3, 4, 5, 6, 12 and 24 hours 
after addition of E2-media. 
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Sequencing and differential expression analysis 
MCF7 cells were lysed and RNA was isolated using the Norgen (Ontario, Canada) Total 
RNA Purification Kit (#17200). Only samples with an RNA Integrity Number (RIN) of 9 or higher, 
as measured by Agilent (Santa Clara, CA) Bioanalyzer 2100, were considered for further 
analysis. Small RNA libraries were generated using the Bioo Scientific (Austin, TX) NEXTflex V2 
kit (#5132-03) and sequenced on the Illumina HiSeq 2000 platforms. Small RNA-seq reads 
were trimmed using cutAdapt (-O 10 –e 0.1)[135] to remove remnants of the 3’-adapter 
sequence, then the first 4 and last 4 nucleotides of small RNA-seq reads were trimmed to 
remove the degenerate nucleotides in the adapters. Subsequent mapping of trimmed reads to 
the human genome and miRNA/isomiR quantification were performed exactly as previously 
described[20]. The threshold used to classify miRNAs as robustly expressed was set at a mean 
of 50RPMM across the time series.  
RNA-seq libraries were generated from the same total RNA isolated above using the 
Illumina (San Diego, CA) TruSeq stranded mRNA library prep kit (#RS-122-2101) and were 
sequenced on the HiSeq2500 (2x50). Reads were aligned to the human genome (hg19) using 
MapSplice (2.1.4)[136], and transcript abundance was quantified using RSEM (v1.2.9)[137]. 
Finally, differentially expressed genes were identified using DEseq2 (1.4.5)[138]. The threshold 
used to classify mRNAs as robustly expressed was set at a mean normalized count of 500 
across the time series to allow us to robustly detect changes in expression that may be well 
below the mean of the time series.  
Clustering 
To cluster the dynamic responses of estrogen regulated genes, 1D interpolation was 
preformed using a piecewise cubic Hermite interpolating polynomial [139] to estimate the 
expression at un-measured time points. Next the response of each gene was subjected to 1D 
wavelet decomposition [140] using a Daubechies 3 wavelet. Finally the vectors of wavelet 
coefficients were hierarchically clustered and split into three clusters. 
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Gene set and miRNA target site enrichment 
Enrichment of the three classes of estrogen responsive genes within GO biological 
processes categories was assessed using the PANTHER overrepresentation test[141]. A 
selection of the most significant categories are depicted in Figure 2E-G.  
miRNA target site enrichment was conducted by (1) identifying the list of miRNA families 
whose members have a mean expression of 50RPMM, (2) identifying lists of “characteristic 
genes” whose change in expression best describes the difference between consecutive time 
points[123], and (3) using our miRNA target site enrichment algorithm (miRhub) [20] to identify 
miRNA families that act as “master regulators” of the “characteristic gene sets”. miRNA target 
site predictions used in the miRhub enrichment algorithm are derived from TargetScan5.2 [79].  
Real time quantitative PCR analysis  
Using total RNA from above, complementary DNA (cDNA) was synthesized using the 
TaqMan miRNA Reverse Transcription kit (Applied Biosystems; Grand Island, NY; #4366596) 
according to the manufacturer’s instructions, or using the High-capacity RNA-to-cDNA kit 
(Applied Biossystems; Grand Island, NY; #4387406). Real-time PCR amplification of miRNAs 
was performed using TaqMan miRNA assays in TaqMan Universal PCR Master Mix (Applied 
Biosystems; Grand Island, NY; #4304437) on a BioRad CFX96 Touch Real Time PCR 
Detection system (Bio-Rad Laboratories, Inc., Richmond, CA). Reactions were performed in 
triplicate using RNU66 as the internal control. Real-time PCR amplification of mRNAs was 
performed using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad Laboratories, 
Inc., Richmond, CA; #1725271) on a BioRad CFX96 Touch Real Time PCR Detection system 
(Bio-Rad Laboratories, Inc., Richmond, CA). Reactions were performed in triplicate using RPS9 
as the internal control. All TaqMan assays used in this study where purchased from Applied 
Biosystems, Inc. (Grand Island, NY) and include: miR-503 and RNU66. 
Luciferase Reporter analysis 
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We utilized a dual luciferase reporter system (GeneCopoeia; Rockville, MD; # 
HmiT018728) in which the 3’-UTR of ZNF217 was fused to the end of Firefly luciferase. The 
construct also contains Renilla luciferase, which can be used as an internal control. Next, we 
mutated the vector to interfere with the binding of the miR-503 “seed” region (nucleotides 2-8) 
using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent; Santa Clara, CA; #200521). 
Two A’s were added in the miR-503 target site of ZNF217 to induce a bulge in the target site 
opposite of nucleotides 3 and 4 of miR-503’s “seed”. MCF7 cells were transiently transfected 
with the wild-type or mutant reporter with or co-transfected with miRIDIAN microRNA Human 
hsa-miR-503-5p mimic (Dharmacon; Lafayette, CO #C-300841-05-0005) and with the vector. 
Luminescence was measured 48 hours after transfection using the Luc-Pair Duo-Luciferase 
Assay (GeneCopoeia; Rockville, MD; # LPFR-P030) on a Promega GloMax Multi+ Detection 
System luminometer. 
Cell proliferation assay 
Cell proliferation was measured using the Click-iT® EdU Alexa Fluor® 488 Imaging Kit 
(Invitrogen; Carlsbad, CA; # C10337). MCF7 cells were transfected with 50nM miR-503 mimic 
or with transfection reagent only and were cultured for 46 or 70 hours. Cells were then pulsed 
with EdU for 2 hours before cells were fixed according to the Click-iT protocol. Finally EdU was 
labeled with Alexa Fluor 488 dye, DNA was stained with Hoechst and were imaged at 20x on an 
inverted fluorescence microscope with a Nikon TI Eclipse camera. Image segmentation analysis 
was performed using the Nikon Elements software package. Ki67 levels were measured using 
the Anti-Ki67 antibody (Abcam; Cambridge, MA; # ab15580). 
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Supplemental Figure 5.1: PCR validation of selected RNAs. Comparison between the 
relative quantitative value (RQV) of selected RNAs as measured by high throughput sequencing 
(y-axis) or RT-qPCR (x-axis). Pearson’s correlation value (r) is shown in red on each plot. 
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Supplemental Figure 5.2: GATA3-like and anti-GATA3-like genes. (A) The expression 
profile of 170 mRNAs that exhibit an expression pattern similar to GATA3. (B) The expression 
profile of 118 mRNAs that exhibit a pattern of expression opposite of that of GATA3. (C) 
Normalized expression of GATA3 and FOXC1 in 1046 samples from The Cancer Genome Atlas 
breast cancer dataset. Pearson’s correlation (r) is shown in red. (D) Opposite expression pattern 
of GATA3 and FOXC1 is consistent with a mutual inhibition relationship. 
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Supplemental Figure 5.3: Top ChEA binding hits for estrogen responsive mRNAs. The ten 
most enriched transcription factor binding sites for estrogen responsive mRNAs in our dataset 
using ChEA. Transcription factors are sorted by p-value ranking. 
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Supplemental Figure 5.4: miR-503 inhibits proliferation. (A) Total EdU and DNA (Hoechst) 
fluorescence in cells from Mock or miR-503 (50nM) transfected MCF7 cells. (B) The percentage 
of MCF7 cells in S-phase during the EdU pulse experiment form Mock or miR-503 (50nM) 
transfected MCF7 cells at 48 or 72 hours post transfection. Significance assessed using a 
student’s t-test (* P< 0.05, **P< 0.01). 
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Supplemental Figure 5.5: Ki67 protein levels in Mock and miR-503 transfected MCF7 
cells. Western blot showing Ki67 protein levels in Mock or miR-503 (50nM) transfected MCF7 
cells at 72 hours post transfection. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Estrogen stimulation of ERα promotes proliferation and survival, but also opposes 
transformation. Utilizing the tools and techniques I developed and described in Chapters 2-4, we 
were able to investigate the temporal response of both mRNAs and miRNAs in MCF7 cells to 
estrogen stimulation. We identify three major patterns of gene expression following estrogen 
stimulation (1) transient, (2) induced, and (3) repressed. Among the genes repressed by 
estrogen stimulation is the oncogene ZNF217, which has been shown to enhance proliferation 
in ovarian [131] and breast cancer [132]. Additionally, we have shown that the estrogen-induced 
miRNA, miR-503, targets the 3’-UTR ZNF217 and that while miR-503 is induced in response to 
estrogen, the oncogene ZNF217 is reduced. Together these observations reveal some of the 
complexity of the estrogen-signaling network, and further highlight the beneficial aspects of the 
estrogen response. Several studies have recently shown that miR-503 may be a potent tumor 
suppressive miRNA. One such study showed that miR-503 targets CCND1 and reduces 
proliferation in both MCF7 and MDA-MB-231 cells (an ER (-) Claudin-low model) [124]. Others 
have shown that miR-503 reduces proliferation and metastasis in prostate cancer [129], in 
osteosarcoma [130], and in hepatocellular carcinoma[133]. Furthermore, loss of miR-503 has 
been reported in several human cancers, and is associated with poor prognosis in cervical 
cancer [134]. The induction of miR-503 in response to estrogen stimulation has anti-proliferative 
effects, likely through its repression of both CCND1 and ZNF217. Combined with the 
information that miR-503 is down regulated in human cancers, these results indicate that miR-
503 presents a new candidate therapeutic option for the treatment of breast cancer. 
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The dynamic map of the response of mRNAs and miRNAs to estrogen stimulation 
generated in this study is a resource that can continue to be mined to identify additional 
interactions relevant to the estrogen response. For example, we identified groups of genes that 
exhibit opposite temporal patterns of expression (the GATA3-like and anti-GATA3-like groups). 
Investigation of the expression of these groups of genes within the TCGA breast cancer dataset 
led us to hypothesize that the genes GATA3 and FOXC1 might be involved in a double negative 
feedback loop. A literature search for these two genes uncovered a study by TKocz et. al. that 
showed knockdown of GATA3 in luminal cells resulted in the expression of basal-like markers 
and cell morphology, while knockdown of FOXC1 in basal-like cells resulted in the expression of 
luminal markers and cell morphology. The GATA3 - FOXC1 network warrants further 
investigation and this mechanism is one example of a system that would benefit from the type of 
study described in Chapter 5. The transition between luminal and basal morphologies in 
response to knockdown of GATA3 in luminal-like cells and FOXC1 in basal-like cells provides 
us with a system that can be studied to identify the steps involved the reprogramming of breast 
cancer cells from a more mild luminal subtype to a more aggressive basal subtype and back. 
Investigation of this system may uncover additional insights into the progression of breast 
cancer. More generally, as most biological processes are dynamic, the type of study described 
in Chapter 5 can be used to investigate any such process.  
One natural extension of the work described in this thesis is to incorporate additional 
types of data. For example, one such data type is the expression of long non-coding RNAs 
(lncRNAs). HTS studies have revealed that as much as 85% of the human genome is 
transcribed, and much of this transcription produces non-coding RNAs[142]. miRNAs are one 
class of short non-coding RNAs, and years of research has revealed some of the features and 
functions of miRNAs. By comparison, the study of long non-coding RNAs is in its infancy. 
Nevertheless, functionality of individual lncRNAs has been demonstrated. For example, the X 
inactive specific transcript (XIST) is involved in X chromosome inactivation [143]. The RNA-seq 
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data described in Chapter 5 can also reveal lncRNAs that respond to estrogen stimulation. A 
preliminary lncRNAs analysis of the data shows that the lncRNA GATA3-AS1 exhibits a similar 
temporal pattern of expression to GATA3. However, GATA3-AS1 fails to recover following the 
dip in express at 2 hours post estrogen stimulation. An examination of estrogen responsive 
lncRNAs may reveal other non-coding RNAs that may play a role in breast cancer. 
Alternative polyadenylation (APA) of mRNAs is prevalent during proliferation and 
development [144,145]. In cancer, widespread shorting of 3’-UTRs has been observed 
[146,147], and the expression of shorter 3’-UTR isoforms is correlated with poor prognosis in 
breast and lung cancer[148]. Although, not discussed in this thesis, we have also collected 
matched 3’-end sequencing data for several time points following estrogen stimulation. These 
data will enable us to identify not only which 3’-UTR isoforms are expressed, but also whether 
3’-UTR isoforms are differentially expressed in response to estrogen. Such information would 
provide another layer of data that can help to uncover the mechanisms underlying the regulatory 
architecture that underlies the estrogen response. As miRNAs bind to their targets primarily 
within the 3’-UTR region, accurate annotation of expressed 3’-UTRs is critical to identifying 
potential miRNA targets. 
In Chapter 5 we identify miR-503 as an estrogen responsive miRNA that inhibits 
proliferation and represses ZNF217. Others have demonstrated that miR-503 also represses 
CCND1[124], and that miR-503 inhibits proliferation in prostate cancer[129], osteosarcoma 
[130] and hepatocellular carcinoma[133]. Another extension of this work would be to investigate 
the estrogen response of miR-503 knockout MCF7 cells generated by deleting the miR-503 
precursor using a CRISPR-Cas9 system[149]. The MCF7-ΔmiR-503 cells could be studied to 
identify any potential phenotypic differences, and the same estrogen response time-course 
could be repeated in the knockout cells. Such a study could lead to further insights into the 
importance of miR-503 in the estrogen response. 
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Finally, the inclusion of additional cell types would greatly improve these data. Other 
ER+ cell lines such as T47D or ZR-75-1 could be exposed to the same estrogen response time-
course to determine if the observations from Chapter 5 are consistent across other ER+ models 
of breast cancer. Such data would more strongly indicate that the estrogen-signaling network in 
breast cancer produces the responses we observed in mRNAs and miRNAs, and that those 
responses are not specific to the MCF7 cell line.  
Overall, the tools and techniques I developed and described in Chapters 2-4 have 
enabled the Sethupathy and Purvis labs to investigate miRNA regulation in numerous cell and 
tissue types. Chapter 5 describes the application of these methods to the field of breast cancer 
and the estrogen response, but these methods have also been applied to the study of Type 2 
diabetes[16,20,21], Crohn's disease [17], Hepatitis B and C [18] and the response of MCF7 
cells to different dynamic expression patterns of the tumor suppressor p53 (unpublished). 
Moreover, the study design described in Chapter 5 can be applied to study the dynamics of any 
biological process.  
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